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The regulation of cytosolic potassium is a convergent factor in cell death programs of many 
mammalian cell types including central nervous system neurons. Physiological levels of potassium 
concentrations can suppress the activation of critical caspases and nucleases necessary for cell 
death. Under physiological conditions, several ion channels and exchangers sustain intracellular 
potassium levels. Conversely, tightly regulated molecular pathways facilitate the depletion of 
intracellular potassium after injury to very low concentrations, enabling cell death mechanisms to 
proceed. Several research groups have shown that preventing the loss of intracellular potassium 
after injury through various approaches can increase the survivability of several cell types. In 
neurons, the main regulator of intracellular potassium after injury is the delayed rectifier potassium 
channel Kv2.1. Strategies aimed to ameliorate Kv2.1-dependent neuronal cell death have been 
investigated over the past several years. We have come to understand that lethal oxidative damage 
set forth unique, zinc-dependent phosphorylation of Kv2.1, leading to enhanced membrane 
channel insertion and elevated potassium efflux currents. Critical to this pathway is the protein-
protein interaction between Kv2.1 and the cell surface soluble NSF attachment protein receptor 
(SNARE) syntaxin 1A (syntaxin). Interrupting this interaction has been shown to improve 
neuronal survival in vitro. In this dissertation, I report several studies that further clarify the 
molecular interactions between Kv2.1 and syntaxin, and provide the first in vivo evidence that 
disrupting the Kv2.1-syntaxin binding is a viable neuroprotective strategy. We explored several 
approaches using both peptide-based and synthetic small molecules as the protective agent. To cap 
off these findings, I provide preliminary data that leverages the hepatitis virus protein NS5A to 
 v 
suppress Kv2.1-dependent cell death in ischemic stroke. We intend for the work presented here to 
serve as the basis to further unravel the role of Kv2.1 in other neurodegenerative conditions and 
eventually make the translational leap to improve clinical treatments. 
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1.0 Introduction 
1.1 The increasing burden of neurodegenerative diseases 
Historical advances in medical practice have led to a very different quality of living from 
merely a century ago. Improved sanitation and disease counter measures have decreased mortality 
across all age groups. While the maximum human lifespan have not increased significantly in 
recent times (Dong et al., 2016), the proportion of the elderly in the population today is the highest 
it has ever been. In 1950, the world’s 65 and over age group accounted for roughly 5% of the 
world’s population, in 2015, this number steadily increased to 8.5% and is projected to reach 12% 
by 2030 and 16.7% by 2050 (He et al., 2016). More nations will begin to have a constriction of 
the population pyramid, and even inversions of the age structure will be observed. This 
demographic transition necessarily indicates a change in the prevalence of certain illnesses and 
contributes to a critical shift in the central focus of modern medicine. Currently in the United States 
and many similar developed nations, heart disease and cancer-related illnesses are the top leading 
causes of death by a large margin, as reported by the Center for Disease Control (CDC). Stroke 
and Alzheimer’s disease, two highly age-correlated neurodegenerative diseases (Murphy et al., 
2018), are also consistently ranked as leading causes of death, currently at 5 and 6, respectively. 
With increases in the average human life span and the population growth rate, neurodegenerative 
diseases are set to rapidly become towering medical and economic burdens in the coming decades. 
Age is, by far, the strongest predictor for most idiopathic neurodegenerative diseases. More 
than three quarters of stroke occurs in the population of ages 65 and up, and the risk for stroke 
doubles for each successive decade after the age of 55 (CDC). Projection of stroke patients in the 
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United States population suggests a rising trend from 3.22% in 2012 to 3.88% in 2030, an increase 
of 3.4 million individuals, accounting for a doubling in direct medical cost from 71.55 billion to 
157.30 billion US dollars (Ovbiagele et al., 2013). Individuals suffering from Alzheimer’s disease 
and related dementias in the United States numbered approximately 5 million in 2014 (1.6% of 
US population) and will expand to 13.9 million people in 2060 (3.3% of US population) (Matthews 
et al., 2019). Direct cost of care for Alzheimer’s disease and related dementias is projected to grow 
from 109 billion in 2010 to 259 billion US dollars by 2040 (Deb et al., 2017). This projected 
increase in the prevalence of ischemic stroke and Alzehimer’s disease represents a lost in the 
quality of life for a large afflicted population and their family members. Despite these growing 
needs, our current treatment options for all these neurodegenerative conditions are wholly 
unsatisfactory.  
The paucity in treatment options for neurodegenerative diseases is not for the lack of 
attempts in development. Preclinically, drug developmental research has had numerous successes. 
But translation of these findings to the clinic has been difficult. Between 1995 and 2005, 430 
potential stroke drugs were evaluated for efficacy in clinical trials globally. Nineteen (4%) have 
reached the market. The few treatments that are mechanistically neuroprotective are currently 
unavailable in the United States for clinical use (Citicoline, a naturally occurring intermediate to 
cell membrane lipids, has been discontinued due to the lack of effect across several clinical trials 
(Shi et al., 2016); Fasudil, a Rho kinase inhibitor and vasodilator, has not been approved in the 
United States after a lengthy legal battle and concerns over liver toxicity (Chen & Wang, 2016)). 
In fact, most currently accepted ischemic stroke treatments rely on the physical re-establishment 
of blood flow, the so-called clot buster drugs or variations of thrombectomy, rather than 
neuroprotective agents. Treatments for Alzheimer’s disease are in a similar state. From 1998 to 
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2017 there have been 146 failed attempts at developing Alzheimer’s drugs (PhRMA report 2018). 
Current treatments for Alzheimer’s disease include the use of cholinesterase inhibitors 
(galantamine, rivastigmine, and donepezil) and the NMDA antagonist memantine. Both groups of 
drugs are known cognitive enhancers (Repantis et al., 2010) and memantine also confer some 
neuroprotective activity by counteracting excitotoxicity (Danysz & Parsons, 2003). Treatments 
designed to target Alzheimer’s disease etiology directly have been the most disappointing 
(recently, see the abandoned projects CREAD 1 and 2, β-amyloid antibodies by Roche, Jan 2019). 
These costly failed clinical trials highlight a rapidly growing need for more effective 
neuroprotective therapies, urgently calling for innovative approaches in combating 
neurodegenerative conditions. 
1.2 Apoptotic cell death in neurodegenerative diseases  
The complexity of the cell death process in neurodegeneration is central to the difficulties 
in developing effective treatments. Distinguished biological features allow us to place the event of 
cell death on a spectrum ranging from the highly precise and contained apoptosis to the 
uncontrolled process that is necrosis. The apoptotic cell death has the specific goal of minimizing 
secondary damage, such as the release of inflammatory factors, to surrounding cells upon cell lysis. 
This is achieved by the activation of a specific class of proteases known as caspases, and caspase-
activated endonucleases that cause DNA degradation (Elmore, 2007). Molecular signals such as 
phosphatidylserine are also presented on membrane surfaces as “eat me” signals to encourage 
phagocytosis by macrophages (Segawa & Nagata, 2015). While apoptotic programs are a 
necessary part of the developmental process and in tissue turnover homeostasis in adults, excessive 
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activation of the cell death program can be observed in pathological states. On the other hand, 
necrotic cell death releases intracellular contents undeterred and can be detrimental to the whole 
organism. More recent experiments found programmed molecular pathways can also lead to 
inflammatory forms of cell death, called necroptosis, and it has been observed in 
neurodegenerative diseases such as Alzheimer’s disease (Caccamo et al., 2017). Realistically, each 
disease is considered to have unique fingerprints of cell death characteristics, including features of 
both apoptosis and necrosis, making a comprehensive neuroprotective treatment exceedingly 
difficult to develop (Chi et al., 2018).  
Focal ischemic stroke is a prominent example of a neurodegenerative condition that 
contains heterogenous cell populations that are undergoing different modes of cell death. At the 
ischemic core, cells experience rapid necrotic cell death due to the severity of the insult and will 
die within a few hours. In contrast, cells in the ischemic penumbra, the perimeter of the ischemic 
site, go through apoptotic programs that can be observed for days (Radak et al., 2017). Elevated 
protein expression related to the activation of caspase activity, including signs of nuclease-
dependent DNA fragmentation, can be found in stroke patient post-mortem brain tissues (Mitsios 
et al., 2007). In Alzheimer’s disease, apoptotic mechanisms are thought to be a significant mode 
of cell death (McCord & Aizenman, 2014; Obulesu & Lakshmi, 2014). Elevated activation of 
executioner caspases can be found in post-mortem patient tissues (Rohn & Head, 2009). β-
amyloid, the central protein underlying several proposed mechanisms of Alzheimer’s disease, 
induces caspase-dependent apoptosis in neurons (Allen et al., 2001). In all cases, the goal of 
neuroprotection is to either reduce the region afflicted by necrotic cell death by alleviating the 
insult or, in the many cases where this is not possible, improve the likelihood of survival in cells 
undergoing apoptotic cell death by limiting the excessive activation of cell death programs.  
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Classical features of cell death programs can be the result of convergent intrinsic and 
extrinsic caspase activation pathways. In the intrinsic pathway, lethal insults such as severe 
oxidative stress cause irreversible damage to mitochondria, leading to the loss of mitochondrial 
membrane potential and the release of cytochrome c into the cytosol. This internal cell death signal 
of cytosolic cytochrome c directly participates in the formation of the apoptotic protease activating 
factor 1 (Apaf-1) oligomeric apoptosome. The Apaf-1 apoptosome then binds and cleaves pro-
caspase-9, activating it and the subsequent executioner caspase cascades (Zou et al., 1999). The 
extrinsic pathway relies on extracellular ligands binding to death receptors of the tumor necrosis 
factor (TNF) receptor superfamily such as TNFR1 and Fas Receptor (FasR). While each of these 
death receptors have specific mechanisms, whether it be regulated gene expression through NF-
kb or extranuclear signal transduction to the mitochondria/apoptosome, they all converge to the 
activation of executioner caspases (Obulesu & Lakshmi, 2014). As cell death programs are 
underway, many stereotypical features of apoptosis can be observed, such as chromosome 
condensation, membrane blebbing, and, perhaps the most visually impressive, the dramatic loss of 
cell volume. While originally assumed to be a passive process, apoptotic cell volume decrease is 
now known as a robust and highly regulated active event during cell death. This dissertation 
focuses on a key contributor to apoptotic volume decrease, particularly in neurons. 
1.3 Apoptotic cell volume decreases and potassium regulation  
Apoptotic volume decrease is an isoelectric loss of cell volume that begins prior to caspase 
activation and is a characteristic observed in most physiological models of programmed cell death 
(Bortner & Cidlowski, 2007). The phenomenon of apoptotic volume decrease is distinct from that 
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of regulatory volume decrease, which only occurs in response to anisotonic conditions, albeit they 
can involve similar molecular pathways (Szabò et al., 1998; Maeno et al., 2000). Compared to the 
rapid adjustments in regulatory volume decrease (within seconds), apoptotic volume decrease 
occurs slowly, within 12-20 minutes of the insult depending on the cell type and death-inducing 
stimulus studied (Bossy-Wetzel et al., 2004; Hessler et al., 2005). While slower, apoptotic volume 
decrease is an active process that is necessary for the activation of caspases and the efficiency of 
apoptotic nucleases (Bortner & Cidlowski, 2002). In fact, typical regulatory elements are often 
overridden during cell death processes, such as the suppression of mechanisms that maintains cell 
volume in healthy conditions (Bortner et al., 2001; Mann et al., 2001).  
Early work evaluating the contributors of apoptotic volume decrease found intracellular 
potassium to be the key ionic component mediating this process, as it is the most abundant and 
osmotically important cation in the cell (Franco et al., 2006). This critical loss of intracellular 
potassium is coupled with the early inhibition of the cell’s ability to uptake potassium through the 
Na-K-ATPase (Nobel et al., 2000; Bortner et al., 2001). Because this loss of cell volume is 
electroneutral, outwardly rectifying chloride channels have been observed to accompany 
intracellular potassium efflux and apoptosis (Szabò et al., 1998). Although chloride blocker can 
prevent cell shrinkage, they do not suppress the activation of caspase and the subsequent DNA 
fragmentation, suggesting that potassium ions specifically are required for suppression of 
apoptotic mechanisms in healthy cells (Wei et al., 2004b). 
Blocking potassium efflux in various ways have been shown to suppress apoptosis and the 
many associated biomarkers. In a number of model systems, the presence of cytoplasmic levels of 
high extracellular potassium (100 mM+) has been shown to prevent the activation of apoptotic 
components, including the externalization of phosphatidylserine, mitochondrial depolarization, 
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and the release of cytochrome c from mitochondria (Thompson et al., 2001). Importantly, caspase-
3 activation is inhibited by physiological levels of intracellular potassium (Bortner & Cidlowski, 
2002). Apoptotic nuclease activity was also shown to be prevented by physiological concentrations 
of intracellularpotassium (100-150 mM) in cell-free assays (Hughes et al., 1997). Oligomerization 
of Apaf-1 and the assembly of the active apoptosome complex is suppressed by physiological 
intracellular concentrations of potassium as well, preventing activation of downstream caspase-9 
cell death cascades (Cain et al., 2001). Interestingly, once assembled, the apoptosome was shown 
to be relatively insensitive to the ionic effects surrounding this complex (Cain et al., 2001). 
The identification of a single potassium channel or mechanism that is universally 
responsible for the efflux of intracellular potassium in all apoptotic model systems has been 
elusive. Early studies showed that the N-type potassium channel Kv1.3 in jurkat T lymphocytes 
and prostate cancer cells appears to mediate cell death. Kv1.2 appears to play a role in the cell 
death of SH-SY5Y neuroblastoma cells following hypoxia and glucose deprivation and Kv1.5 
contributes to the cell death of COS-7 and pulmonary artery smooth muscle cells (Bortner & 
Cidlowski, 2007). Kv1.1 and Kv1.3 contribute to retinal ganglion neuron degeneration after injury 
through both neuronal and inflammatory microglia mechanisms (Koeberle & Schlichter, 2010). 
Potassium channels that are not voltage-gated have also been implicated, such as the calcium-
activated IKCa1 channels in T lymphocytes (Elliot & Higgins, 2003). These plethora of reports 
across various cell types indicate that ion channel-mediated loss of intracellular potassium is likely 
a redundant mechanism and one may compensate for another during prolonged inhibition of one 
channel during cell death. Furthermore, reports indicate that mechanisms of apoptotic volume 
decrease can occur independently from the cell nucleus and other organelles (Bratosin et al., 2001; 
Lang et al., 2003). Interestingly, in some model systems, the inhibition of potassium channels has 
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been shown to induce cell death (Choi et al., 1999; Kim et al., 2000). However, in the example of 
these studies, it is expected that the disruption of basal functions to be deleterious in healthy cells. 
1.4 Kv2.1 in neuronal cell death   
Kv2.1 is a delayed rectifier potassium channel with 6 transmembrane domains that can 
form both homomers and heterotetramers with other Kv, such as Kv2.2 (Kihira et al., 2010), the 
electrically silent voltage gated potassium channel subunits (KvS) (Kv5, Kv6, Kv8, and Kv9 
(Bocksteins, 2016), and the EAG family channels Kv10.1 and Kv11.1 (Ottschytsch et al., 2002)). 
Kv2.1 also contains large intracellular N- and C-terminal domains for non-conducting functions 
(Feinshreiber et al., 2010; Fox et al., 2015; Greitzer-Antes et al., 2018) and for phosphoregulation 
of its ion channel functions (Park et al., 2006). Kv2.1 is encoded by KCNB1, found on the long 
arm of the human chromosome 20q13.13, and it is widely expressed throughout the central nervous 
system, exclusively in neurons. Kv2.1 is also expressed in several other organs, including the lung, 
the pulmonary artery, the heart, the pancreas, and the liver. De novo mutations of the KCNB1 gene 
have been reported to cause frequent infantile epileptic seizures (~11 months) that subside later in 
age (~4-6 years) but evolve into encephalopathy with severe intellectual disabilities and autism 
(Calhoun et al., 2017; Marini et al., 2017). Experimental findings revealed that Kv2.1 is an 
important regulator of intrinsic excitability (Mohapatra et al., 2009), and that Kv2.1 knockout mice 
exhibit seizure propensity (Speca et al., 2014). Besides its functions in regulating neuronal 
excitability, Kv2.1 is important in many cell types for the depletion of intracellular potassium 
concentration during cell death. Various routes of blocking Kv2.1 efflux have been found to be 
protective. In neurons, lethal insults induce a Kv2.1-dependent pronounced increase in potassium 
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currents that can be blocked with the expression of a dominate negative Kv2.1 construct (Pal et 
al., 2003). These findings suggest that Kv2.1 is a key mediator for the apoptotic depletion of 
intracellular potassium in neurons. 
The upstream pathways leading up to the enhanced Kv2.1 current in neurons have been 
carefully dissected. After significant oxidative insults, oxidized metal-binding proteins release free 
zinc into the cytosol from various compartments of the cell, such as metallothionine, mitochondria, 
and other organelles (McCord & Aizenman, 2014; Maret, 2019). This rise in free zinc activates 
zinc-dependent signaling pathways that can generate an optimal environment for cell death. These 
pathways include the zinc-dependent dual phosphorylation of Kv2.1 specifically by Src and p38 
MAPK at Kv2.1 residues Y124 and S800, respectively and sequentially (McLaughlin et al., 2001; 
Pal et al., 2003; Redman et al., 2007; Redman et al., 2009; He et al., 2015). These modifications 
to the channel increase the interaction between Kv2.1’s intracellular C-terminus domain and the 
SNARE protein syntaxin 1A (syntaxin). Subsequently, an upregulation of de novo channel 
insertion into the plasma membrane leads to the critical enhancement of K+ efflux in damaged 
neurons, generating the aforementioned necessary low potassium intracellular environment for 
caspase and nuclease activity. The topic of the Kv2.1-syntaxin interaction is the core interest of 
this dissertation and is further elaborated upon in section 1.7. 
As mentioned, many potassium channels may mediate the loss of intracellular potassium 
in dying cells. Kv2.1 is particularly important because it is responsible for mediating the majority 
of the delayed rectifier currents in Kv2.1-expressing neurons, such as those in the hippocampus 
(Murakoshi & Trimmer, 1999), which are especially sensitive in neurodegenerative conditions. 
The cell death mechanisms of Kv2.1 has also been shown to be ubiquitous, as transient 
introduction of Kv2.1 in Chinese Hamster Ovary (CHO) cells, which does not endogenously 
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express any voltage-gated ion channels, increases the susceptibility of the CHO cell to apoptotic 
agents (Pal et al., 2003). This is indicative of an intimate and highly refined relationship between 
the Kv2.1 cell death pathway and the endogenous cell death programs. Combined with the fact 
that Kv2.1 is widely expressed in many cell types and in CNS neurons, studying Kv2.1-mediated 
cell death represents an important facet of understanding and treating many diseases involving 
cellular degeneration. 
1.5 Oxidative stress and zinc dysregulation in neurodegenerative diseases 
The involvement of elevated zinc signaling in Kv2.1-dependent neuronal cell death is an 
important indication of the Kv2.1-dependent pathway’s relevance in neurodegenerative diseases. 
Zinc is the second most abundant biological trace element after iron, and its homeostasis is 
regulated by large families of transporters (Kambe et al., 2015). It is known to serve indispensable 
roles in the function of over 2000 proteins, including more than 300 enzymes (Andreini et al., 
2006; Marreiro et al., 2017). Zinc has been recognized for its abilities to activate the metal-
transcription factor-1 (MTF-1), which governs the expression of metallothionine, a potent heavy 
metal chelator and free radical scavenger (Ruttkay-Nedecky et al., 2013). MTF-1 also activates 
the expression of the selenoprotein-1 (Sepw1) gene, which encodes an antioxidant glutathione-
binding protein that scavenges free radicals (Bonaventura et al., 2015). Zinc and copper are also 
core structural components of the Cu/Zn type superoxide dismutase (Cu-Zn-SOD), which is 
essential for antioxidant functions and its mutations has been found to be associated with 
neurodegenerative diseases such as amyotrophic lateral sclerosis (Valentine & Hart, 2003).  
 11 
Oxidative stress is a ubiquitous component of almost all neurodegenerative diseases. While 
generally accepted as an important regulator of proper cellular response to oxidative stress, zinc, 
when in dyshomeostasis, has been shown to also play detrimental roles in brain diseases (Marreiro 
et al., 2017; Portbury & Adlard, 2017). Heightened activity in glutamatergic terminals in 
excitotoxic conditions can promote excess co-release of zinc, which enters through kainate and/or 
calcium-permeable AMPA receptor channels (Galasso & Dyck, 2007). This disruptive rise in 
cytosolic zinc can not only cause overactivation of certain zinc-dependent pathways, including 
those that promotes cell death (Portbury & Adlard, 2017), but also cause prolonged mitochondria 
dysfunction and reactive oxygen species generation (Galasso & Dyck, 2007). In Alzheimer’s 
disease, zinc appears to be a key structural component in the massive insoluble β-amyloid 
aggregates (Craddock et al., 2012). Because of the zinc dyshomeostasis and the general increase 
in detrimental roles of zinc during many disease states, we believe that the zinc-dependent Kv2.1 
cell death pathway can be ubiquitously activated as well. Indeed, evidence of Kv2.1-dependent 
cell death have been found in many cellular injury models specific to several diseases in the past 
decades, some of these examples are discussed below. 
1.6 Evidence of Kv2.1 in neurodegenerative diseases 
While the importance of zinc signaling in neurodegenerative diseases is a well-established 
fact, direct evidence for the involvement of Kv2.1 is just beginning to surface. Initial studies in 
vitro found that insults that simulate specific diseases can both raise intracellular zinc levels as 
well as elicit the death-permitting increase in potassium currents. In rat primary culture cortical 
neurons, treatments with a thiol-oxidant can induce cytosolic zinc release and enhance Kv2.1 
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currents (Aizenman et al., 2000). Activated microglia, a strong indicator of neuroinflammation in 
several diseases (Perry et al., 2010), can also induce an increase in cytosolic zinc and in Kv2.1 
currents (Knoch et al., 2008). The neurotoxin 6-hydroxydopamine (6-OHDA) acts as an inhibitor 
to mitochondria complex I and IV and auto-oxidizes to generate damaging free-radicals (Glinka 
et al., 1997).  Because of its ability to cause massive degeneration of dopaminergic neurons, 6-
OHDA has been used in models of Parkinson’s disease for decades (Simola et al., 2007). Not 
surprisingly, treatments of 6-OHDA can induce an increase in cytosolic zinc (Sheline et al., 2013) 
and elicit the increase in death-permitting Kv2.1 currents, which can be blocked to ameliorate 
neuronal cell death (Redman et al., 2006). Oxygen-glucose deprivation (OGD), an in vitro model 
of cerebral ischemia, also induces cytosolic zinc release and Kv2.1-dependent cell death that can 
be ameliorated by blocking Kv2.1 currents (Wei et al., 2004a; Yuan et al., 2011). In vivo evidences 
are beginning to surface. In rats, elevated delayed rectifier current can be observed after ischemic 
stroke in the hippocampus (Wu et al., 2015), where Kv2.1 is the major contributor of delayed 
rectifier currents (Murakoshi & Trimmer, 1999). This is consistent with the fact that broad 
spectrum potassium channel blockers are known to be protective in various stroke models (Wei et 
al., 2003). With relevance to Alzheimer’s disease, treatments of neurons with β-amyloid also elicits 
neurotoxicity dependent on enhanced Kv2.1 current (Yu et al., 1998). 
An alternate model of Kv2.1-dependent neuronal cell death, focuses on the oligomerization 
of Kv2.1 after oxidative damage and has also found convincing evidence in several neurological 
diseases. Unlike the channels in the enhanced potassium currents pathway, oligomerized Kv2.1 do 
not conduct (Wu et al., 2013). Through the use of transgenic animals that express a Kv2.1 point 
mutation that cannot be oxidized (Kv2.1 Tg-C73A), experimental findings confirmed the 
involvement of Kv2.1 oligomerization in neuronal cell death in a mouse traumatic brain injury 
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model (Yu et al., 2016) and in aging-related cognitive impairments (Yu et al., 2019). Decreased 
Kv2.1 function was found in Alzheimer’s disease mouse model (3xTg-AD) and increases neuronal 
excitability in the hippocampus (Frazzini et al., 2016). The Kv2.1 Tg-C73A mice was later shown 
to resistant to the neurological deficits of the 3xTg-AD genotype and that increased oligomerized 
Kv2.1 was found in human patients of Alzheimer’s disease (Yu et al., 2018). Altogether, we 
believe these findings are strong indications that Kv2.1-dependent cell death mechanisms are 
present in several neurodegenerative diseases and is therefore an important topic of study. 
1.7 The Kv2.1-syntaxin interaction 
Kv2.1 has several binding partners through its large cytosolic domains. For example, the 
neuronal adhesion protein amphoterin-induced gene and ORF (AMIGO) acts as an auxiliary 
subunit to increase Kv2.1 conductance (Peltola et al., 2011). Non-conducting submicron Kv2.1 
clusters are formed by the interaction between Kv2.1 and the endoplasmic reticulum anchoring 
proteins VAPA and VAPB, which has been observed to act as a protein trafficking hub (Fox et al., 
2013; Fox et al., 2015; Johnson et al., 2018; Kirmiz et al., 2018). And perhaps most prominently 
studied are the direct interactions between Kv2.1 and members of the SNARE complex, including 
SNAP-25 (MacDonald et al., 2002), VAMP2 (Lvov et al., 2008), and, of interest to this 
dissertation, syntaxin 1A (Leung et al., 2003). These interactions, particularly the one with 
syntaxin, have been shown to be important for exocytosis and vesicle fusion in several cell types. 
In neuroendocrine cells, the Kv2.1-syntaxin interaction facilitates exocytosis of dense core vesicles 
independently of Kv2.1’s ion channel role (Singer-Lahat et al., 2008). In pancreatic β-cells, the 
Kv2.1-syntaxin interaction modulates the release of insulin. Specifically, clustered Kv2.1 domains 
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in secretory β-cells are known to facilitate insulin granule release through the selective binding of 
specific Kv2.1 regions to syntaxin 1A or syntaxin 3 to elicit the secretion of selective granules 
populations (Zhu et al., 2013; Greitzer-Antes et al., 2018).  
In dying neurons, the interaction between Kv2.1 and syntaxin is essential for increasing 
Kv2.1 channel insertion and the expression of enhanced currents. Blocking the increase in 
interaction between Kv2.1 and syntaxin by mutating either Y124 or S800 to alanine prevents the 
currents from becoming large and halts the cell death functions of Kv2.1 (Redman et al., 2007; 
Redman et al., 2009). Pseudo-phosphorylated S800D or S800E Kv2.1 constitutively express 
enhanced potassium currents (Redman et al., 2007). The interaction between Kv2.1 and syntaxin 
is mediated by the proximal Kv2.1 C-terminus domain termed C1a (a.a. 411-522; as opposed to 
the more distal C1b (a.a. 523-621) and C2 (a.a. 634-853) regions or the N-terminus (a.a. 1-182)) 
(Leung et al., 2003). We demonstrated that the Kv2.1 C1a domain disrupts the Kv2.1-syntaxin 
interaction in co-immunoprecipitation and suppresses the enhanced death-permitting currents 
(McCord et al., 2014). The overexpression of C1a is neuroprotective in cortical culture neurons 
challenged with activated microglia (McCord et al., 2014). By evaluating the ability of smaller 
Kv2.1 C1a fragments to inhibit enhanced Kv2.1 currents, the binding region was further narrowed 
down to residues 441-522 (McCord et al., 2014). These results indicate that disrupting the Kv2.1-
syntaxin interaction may be a viable neuroprotective strategy. To realize this translational 
opportunity, we look to successful examples of targeting protein-protein interactions in 
neuropathies based on ion channel functions. 
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1.8 Channel-targeted investigative approaches to neuroprotection 
Ion channel modulation has been a prominent focus in the treatment of many diseases, 
including those neuronal in origin. For example, in the treatment of epileptic seizure through anti-
epileptic drugs (AED), the AEDs includes those that targets sodium channels, calcium channels, 
and both GABA and glutamate receptors (Waszkielewicz et al., 2013). Traditionally, drug 
treatments for these conditions focused on the direct blockade or opening of the channel in 
question. However, this approach can detrimentally affect typical channel activity and cause 
debilitating side effects, such as arrhythmia and respiratory failure, as has been found in the case 
of blocking potassium channels systemically (Graham, 1950; Iwaki et al., 1987; Nattel, 2008). 
More recently, a new peptide-based approach has emerged for targeting the interactions of the 
channel with a regulatory protein as a non-direct approach to modulate channel function. To do 
this, it is sometimes necessary to further understand the specific interactions between the binding 
partners. In 1990, Frank and colleagues presented the SPOT synthesis method that greatly 
improved the feasibility of these studies (Frank et al., 1990; Frank, 2002). SPOT synthesis allows 
the rapid and cost-effective synthesis of peptide arrays that transverse a known region of a protein, 
the array can then be probed using a protein of interest. The results of these experiments provide 
insights to the amino acid sequences that can interact with the protein used in the probing, which 
can be further leveraged to design a peptide-based molecule capable of competitive binding to the 
target protein, thus blocking a specific interaction with the channel. 
There are a few highly successful examples of using this research approach to target ion 
channels in neuronal disorders. In the expression of neuropathic pain, the interaction between 
CaV2.2 and collapsing response mediator protein-2 (CRMP2) was found to increase calcium 
influx and enhance excitability in small-diameter sensory neurons in the spinal cord. It is known 
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that CRMP2 binds CaV2.2 via a region within its three CaV-binding domain (CBD1-3) (Brittain 
et al., 2009). Using the peptide SPOT array, the essential binding sequence between CRMP2 and 
CaV2.2 was found to be a 15-amino acids sequence within CBD3. By conjugating this sequence 
(CBD3) to the cell- and blood brain barrier-permeant domain HIV TAT (TAT), the resulting 
peptide (TAT-CBD3) can competitively bind CaV2.2, effectively preventing its interactions with 
CRMP2 and reduce pain sensitivity after injury (Brittain et al., 2011b). TAT-CBD3 was later found 
to also have neuroprotective properties in rodent models of traumatic brain injury and ischemic 
stroke (Brittain et al., 2011a; Brittain et al., 2012a). 
In a clinical example, the discovery of NA-1 (TAT-NR2B9c) is a breakthrough evidence 
that TAT-linked peptides can be translationally successful for neurodegenerative diseases 
(Ballarin & Tymianski, 2018). TAT-NR2B9c is made up of the TAT domain and the last 9 C-
terminal residues of NMDAR GluN2B, allowing the peptide to disrupt the binding between 
GluN2B and the N-terminus of nNOS, which is known to confer NMDA receptor-mediated 
excitotoxicity. Tymianski and colleagues proceeded to evaluate TAT-NR2B9c in various models 
of ischemic stroke, in which excitotoxicity is a prominent player (Sattler & Tymianski, 2001). 
Rigorous evaluation of TAT-NR2B9c found effectiveness in ameliorating stroke damage in 
several rodent models as well as in rhesus macaques (Cook et al., 2012). TAT-NR2B9c then 
demonstrated clinical effectiveness in phase II clinical trials (ENACT, NCT00728182) completed 
in 2012, which found TAT-NR2B9c to significantly reduce embolic stroke infarct size in patients 
that undertook an endovascular procedure against brain aneurysm. Current phase III clinical trials 
are being carried out in cities around the world for use in neuroprotection after ischemic stroke 
(USA, Australia, Canada, Germany, Ireland, Korea, Sweden, and the UK; ESCAPE-NA1 
NCT02930018, FRONTIER NCT02315443). This rare, potentially successful story of TAT-
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NR2B9c’s translation demonstrated that TAT-linked peptides based on the disruption of an ion 
channel’s interaction with another protein is a proven therapeutic strategy for clinical applications.  
1.9 Thesis Goals 
The goal of this dissertation is to explore the neuroprotective potentials of interrupting the 
Kv2.1-syntaxin interaction. While it has been known for decades that the modulation of potassium 
movement can improve survivability in several cell types, a translatable molecular target has not 
been identified. Finding a treatment that does not directly interfere with the channel’s 
physiological roles is an important aspect of a well-tolerated treatment, as side effects themselves 
can be as debilitating as the symptoms, by way of which many clinical trials may have failed. 
Furthermore, while the Kv2.1 cell death pathway has been extensively studied in rodent primary 
neuronal cultures, it has, heretofore, not been shown as a viable therapeutic method in vivo. To 
begin, we utilized the SPOT peptide synthesis method to identify the interacting entity between 
Kv2.1 and syntaxin. From this, we generate a channel-derived TAT-linked peptide to disrupt 
Kv2.1-syntaxin binding, as with the strategy described above (Chapter 2). Using details observed 
in the peptide SPOT array, we further carried out molecular simulations of Kv2.1 and syntaxin, 
uncovering precise molecular mechanisms in the binding of these two proteins (Chapter 3). Lastly, 
we explored an alternative solution for neurodegenerative diseases in the form of adeno-associated 
virus treatment with a cargo that inhibits the Kv2.1-syntaxin interaction upstream (Chapter 4). 
These are important studies in the scope of a world where neuroprotective treatments are sparse, 
and the burden of neurodegenerative diseases is continuing to climb at an alarming rate. 
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2.0 Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in 
Ischemic Stroke 
2.1 Section Summary 
The voltage-gated K+ channel Kv2.1 has been intimately linked with neuronal apoptosis. 
After ischemic, oxidative, or inflammatory insults, Kv2.1 mediates a pronounced, delayed 
enhancement of K+ efflux, generating an optimal intracellular environment for caspase and 
nuclease activity, key components of programmed cell death. This apoptosis-enabling mechanism 
is initiated via Zn2+-dependent dual phosphorylation of Kv2.1, increasing the interaction between 
the channel’s intracellular C-terminus domain and the SNARE (soluble N-ethylmaleimide-
sensitive factor activating protein receptor) protein syntaxin 1A. Subsequently, an upregulation of 
de novo channel insertion into the plasma membrane leads to the critical enhancement of K_ efflux 
in damaged neurons. Here, we investigated whether a strategy designed to interfere with the cell 
death-facilitating properties of Kv2.1, specifically its interaction with syntaxin 1A, could lead to 
neuroprotection following ischemic injury in vivo. The minimal syntaxin 1A-binding sequence of 
Kv2.1 C terminus (C1aB) was first identified via a far-Western peptide screen and used to create 
a protherapeutic product by conjugating C1aB to a cell-penetrating domain. The resulting peptide 
(TAT-C1aB) suppressed enhanced whole-cell potassium currents produced by a mutated form of 
Kv2.1 mimicking apoptosis in a mammalian expression system, and protected cortical neurons 
from slow excitotoxic injury in vitro, without influencing NMDA-induced intracellular calcium 
responses. Importantly, intraperitoneal administration of TAT-C1aB in mice following transient 
middle cerebral artery occlusion significantly reduced ischemic stroke damage and improved 
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neurological outcome. These results provide strong evidence that targeting the proapoptotic 
function of Kv2.1 is an effective and highly promising neuroprotective strategy. 
2.2 Introduction 
Voltage-gated potassium channels (Kv), key regulators of cellular excitability, play an 
important role in cell death processes underlying several neurodegenerative conditions, including 
stroke (Shah & Aizenman, 2014). At physiological concentrations, intracellular K+ suppresses 
caspase function, inhibits active nuclease activity, as well as limits apoptosome formation (Hughes 
& Cidlowski, 1999; Yu, 2003). Thus, in order for cell death cascades to proceed, intracellular K+ 
concentrations must decrease. In the central nervous system, the delayed rectifier K+ channel 
Kv2.1 plays a prominent role in this process, particularly in cortical, hippocampal, and nigral 
neurons (Pal et al., 2003; Redman et al., 2006; Shen et al., 2009; Shepherd et al., 2012). This cell 
death-enabling mechanism is initiated by intracellular free Zn2+ released from oxidized metal-
binding proteins and compromised organelles (Aizenman et al., 2000; Sensi et al., 2003; Knoch et 
al., 2008; Aras et al., 2009a; McCord & Aizenman, 2013; Granzotto & Sensi, 2015; Medvedeva 
et al., 2017).  Zn2+, in turn, activates a dual kinase-mediated process, resulting in the sequential 
phosphorylation of the intracellular Kv2.1 residues Y124 and S800 by Src and p38 MAPK, 
respectively (Redman et al., 2007; Redman et al., 2009; Shepherd et al., 2012; He et al., 2015). 
These channel phosphorylation events increase a Ca2+/CaMKII-dependent interaction between 
the proximal C-terminus of Kv2.1, termed C1a (Singer-Lahat et al., 2007; Singer-Lahat et al., 
2008), and the SNARE protein syntaxin 1A (STX1A), promoting de novo channel incorporation 
into the plasma membrane and the associated apoptosis-permitting K+ efflux in dying cells (Pal et 
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al., 2006; McCord & Aizenman, 2013; McCord et al., 2014).  Notably, the increased surface 
expression of functional Kv2.1 channels in vitro generally occurs after a delay of approximately 
three hours following the initiation of the injurious event (McLaughlin et al., 2001). 
Experimental manipulation of this pathway at several checkpoints has strongly suggested 
that inhibition of the pro-apoptotic function of Kv2.1 has therapeutic potential. Non-
phosphorylatable point mutations of either Y124 or S800 Kv2.1 residues, inhibition of upstream 
kinases, or interfering with STX1A function have all led to a blockade of pro-apoptotic channel 
trafficking and are protective in in vitro models of neurodegeneration (McLaughlin et al., 2001; 
Aras & Aizenman, 2005; Redman et al., 2007; Redman et al., 2009; McCord & Aizenman, 2014). 
Not surprisingly, suppressing delayed rectifier currents directly is sufficient for improving 
neuronal survival both in vitro (Pal et al., 2003; Yuan et al., 2011) and in vivo (Wei et al., 2003). 
However, blockers of delayed rectifier currents can have significant effects on cardiomyocyte 
repolarization, and are associated with potentially serious side effects, such as ventricular 
tachycardia and respiratory failure (Graham, 1950; Iwaki et al., 1987; Nattel, 2008), making them 
less than ideal candidates for central nervous system pharmacotherapy. As such, the identification 
of an approach to target the cell death-specific elements of Kv2.1 is an essential step towards 
realizing the neuroprotective potential of targeting this channel. With this in mind, we report the 
generation of a cell-permeant, highly neuroprotective peptide construct (TAT-C1aB), derived from 
a heretofore unidentified minimal, 9 amino acid (a.a.), STX1A-binding Kv2.1 sequence coupled 




2.3.1  Establishing the sequence of TAT-C1aB 
To identify the minimal Kv2.1 C-terminal sequence that can bind syntaxin 1A (STX1A), a 
far-western assay (Brittain et al., 2011b) was performed on a peptide spot array of seventy-six 15 
a.a. sequences derived from Kv2.1, spanning residues 451 to 540 (Rattus norvegicus; Accession # 
NP_037318.1; (McCord & Aizenman, 2014)) in 1 a.a. overlapping steps (Fig. 1A). STX1A-
enriched lysates derived from Chinese Hamster ovary (CHO) cells overexpressing the SNARE 
protein were used to probe against the bait Kv2.1 peptides. Subsequent immunofluorescence 
revealed two strongly interacting fragments flanking a region of high STX1A binding, highlighted 
in red and blue in Figs. 1A and 1B. These two fragments contain an overlapping 9 a.a. sequence, 
HLSPNKWKW from N- to C-terminus, corresponding to rat Kv2.1 a.a. residues 478-486. Of note, 
this exact sequence is present in mouse Kv2.1, corresponding to a.a. 482-490 (Mus musculus; 
Accession # NP_032446.2). This sequence likely represents the minimal Kv2.1 C-terminus (C1a) 
STX1A-binding sequence (C1aB).  Addition of the HIV TAT cell-permeable domain to the N-
terminus of C1aB yielded TAT-C1aB: YGRKKRRQRRRHLSPNKWKW (Fig. 1C). A second set 
of membranes were used to confirm a displacement of the spotted peptides to STX1A by TAT-
C1aB (100 uM, n=4; Figs 1A, 1B). A BLAST search of C1aB revealed no identical sequence in 
any other mammalian protein, with only an analogously similar (77%), but not identical, sequence 
in the Kv2.1 cognate Kv2.2 (HLSPSRWKW, Rattus norvegicus and Mus musculus; Accession #’s 
NP_446452.2 and NP_001091998.1, respectively), a channel that has not yet been implicated in 
apoptotic processes, possibly as it lacks a p38 target site analogous to Kv2.1 S800 and flanking 
sequences. Randomizing the C1aB domain of the Kv2.1-derived, STX1A-binding peptide yielded 
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a scrambled control (TAT-SC; YGRKKRRQRRRNLKWSHPKW). BLAST search of the 
scrambled C1aB sequence resulted in no identifiable mammalian proteins. A diagram 
summarizing our overall experimental approach is illustrated in Figure 2, where we hypothesize 
that the isolated STX1A-binding sequence in TAT-C1aB competes for and prevents the increase 
of functional Kv2.1 channels on the plasma membrane during apoptosis and is thus 
neuroprotective. 
2.3.2  TAT-C1aB suppresses apoptotic Kv2.1-mediated K+ currents and provides 
neuroprotection from “slow” excitotoxicity in vitro without influencing NMDA-evoked Ca2+ 
responses 
Previously, we demonstrated that p38 MAPK phosphorylates Kv2.1 at serine residue S800 
to induce the pro-apoptotic increase in K+ currents (Redman et al., 2007). A point mutation of the 
serine to a negatively charged a.a. (E or D) at this position results in apoptotic-like enhanced 
currents in the CHO cell expression system, provided that tyrosine residue Y124 remains intact 
(Redman et al., 2007; Redman et al., 2009; He et al., 2015). It is noteworthy that CHO cells do not 
express any endogenous voltage-gated K+ channels (Yu & Kerchner, 1998), but contain all 
relevant signaling components that lead to pro-apoptotic trafficking of Kv2.1 (Pal et al., 2003; 
Aras & Aizenman, 2005). This offers an advantageous preparation to evaluate the effects of the 
peptide, as it focuses on the STX1A binding-mediated insertion process itself, in the absence of 
potentially confounding signaling events and other apoptosis-related processes.  We observed that 
overnight exposure to 10 µM TAT-C1aB beginning immediately following the transfection 
protocol significantly prevented Kv2.1(S800E)-mediated enhanced currents. In fact, current 
densities in TAT-C1aB treated, Kv2.1(S800E)-expressing CHO cells were not different from those 
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observed in CHO cells expressing wildtype (WT) Kv2.1 (Fig. 3A). Importantly, the identical TAT-
C1aB treatment did not reduce the current density of WT Kv2.1 channels, indicating that normal 
channel trafficking was not affected by the peptide. Moreover, the control, scrambled peptide 
TAT-SC (10 µM) had no measurable effects on the current density of either Kv2.1 construct (Fig. 
3A).  Although these results strongly suggest that TAT-C1aB prevents apoptotic trafficking of 
Kv2.1, a non-equivocal demonstration of this process will require single particle tracking of 
fluorescently labeled channels with techniques such as total internal reflection microscopy (TIRF). 
As TAT-C1aB could effectively prevent enhanced, pro-apoptotic Kv2.1 current, we next 
evaluated whether the peptide would be neuroprotective in an in vitro neuronal system. 
Embryonically-derived rat cortical cultures were treated with 100 µM DL-threo-beta-
benzyloxyaspartate (TBOA) at 25-29 days in vitro (DIV), in the absence or the presence of 0.3, or 
1 µM of either TAT-C1aB or TAT-SC. TBOA, like other glutamate transporter blockers, elicits 
slow NMDA receptor-mediated excitotoxicity in neuronal cultures (Blitzblau et al., 1996; Wang 
et al., 1998). We opted for this cell toxicity model as it has long been established that relatively 
mild exposure to NMDA receptor agonists, over long periods of time, can induce apoptotic injury 
(Bonfoco et al., 1995; Leist & Nicotera, 1998). Moreover, apoptotic excitotoxic stimuli can elicit 
K+ current increases (Yao et al., 2009), and NMDA receptor activation has been closely associated 
with ischemic stroke injury (Meldrum et al., 1987; Aarts et al., 2002).  Within 24 h, TBOA 
incubation led to the appearance of dendritic and membrane blebs. Critically, the presence of 1 
µM TAT-C1aB seemed to be sufficient to ameliorate the TBOA-mediated toxicity, as visualized 
via prior transfection of the neurons with eGFP (Fig. 3B). To quantify the degree of cellular 
damage induced by TBOA and neuroprotection via TAT-C1aB, a lactate dehydrogenase (LDH) 
viability assay was performed 24 h after TBOA treatment. The release of long-lived cytosolic 
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proteins, such as LDH, is indicative of compromised cellular integrity (Koh & Choi, 1987; Aras 
et al., 2001). In corroboration with our qualitative assessment, we found that TAT-C1aB treatment 
significantly decreased TBOA-induced injury in cortical cultures. In contrast, TAT-SC afforded 
no neuroprotection (Fig. 3C). 
Finally, we evaluated whether TAT-C1aB could directly influence NMDA-evoked Ca2+ 
responses. Intracellular Ca2+ recordings were performed as described earlier (Aizenman et al., 
1990; Reynolds et al., 1990) in neurons that had been exposed to 1 µM of either TAT-C1aB or 
TAT-SC overnight (~18 h), until just immediately prior to recordings.  Fura-2 measurements 
revealed that initial Ca2+ responses to 30 µM NMDA + 10 µM glycine, as well as delayed calcium 
dysregulation profiles (Brittain et al., 2012b) were not significantly different between both groups 
of cells (50 cells per coverslip; n=3 coverslips per group. Total 150 cells per condition; Fig. 4).  
These data strongly suggest that the neuroprotective actions of the peptide occur well downstream 
from NMDA receptor activation, as predicted by our model (Shah & Aizenman, 2014) and by the 
observed delayed enhancement of apoptotic potassium currents following injury (~3 h) described 
in prior work (McLaughlin et al., 2001). 
2.3.3  TAT-C1aB provides neuroprotection in vivo 
Once we established that TAT-C1aB was effective in both inhibiting pro-apoptotic Kv2.1-
mediated currents and providing neuroprotection in vitro, we evaluated the in vivo efficacy of 
TAT-C1aB using a transient ischemic stroke model. First however, we investigated whether 
intraperitoneal (i.p.) administration of TAT-C1aB in mice reached the CNS vasculature within a 
therapeutically relevant timeframe. For this purpose, a fluorescein (FitC) fluorophore was 
conjugated to the C-terminus of TAT-C1aB for live in vivo 2-photon imaging in young adult 
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C57BL/6J male mice (24-29g; n=3). A single i.p. injection of TAT-C1aB-FitC (6 nmol/g) was 
administered after a stable imaging position had been reached at 100-200 µm depth from the 
cortical surface through a craniotomy window over the temporal cortex. A rapid rise in FitC 
fluorescence throughout cerebral vessel structures was observed within 10 minutes of the i.p. 
injection (Fig. 5A). Vessel fluorescence intensity continued to increase and peaked at 30 minutes 
after the injection (Fig. 5B).  
Further, we confirmed CNS penetration by the TAT peptide using low power fluorescence 
microscopy. After complete saline transcardial perfusion, animals previously injected with TAT-
C1aB-FitC (6 nmol/g) were found to present increased fluorescent signal throughout the brain, 
when compared to animals injected with the non-fluorescent TAT-C1aB (Fig. 5C). These findings 
are in line with previous characterization of the CNS penetrance of other TAT-linked peptides 
(Schwarze et al., 1999; Stalmans et al., 2015). Because other TAT-linked peptides have been 
shown to positively influence CNS neurons in various animal models of ischemic stroke (Kilic et 
al., 2006; Brittain et al., 2011a; Cook et al., 2012; Zou et al., 2013), and based on our own 
observations here, we concluded that TAT-C1aB can reach its intended target in a therapeutically 
realistic fashion following an i.p. injection. Our observations, in fact, directly confirm that a TAT-
linked peptide can rapidly be detected within the brain vasculature and brain parenchyma 
following a peripherally i.p.-administered injection.  
In addendum to the original publication, lower panels of Fig. 5C shows that without the 
conjugation of the TAT domain, FitC cannot by itself enter the brain parenchyma. 
The Longa method of transient middle-cerebral artery occlusion (MCAO) (Longa et al., 
1989) was used in young adult C57BL/6J mice (Jackson, ages 8-10 wks, male, 24-29g; n=67 for 
entire study) to evaluate TAT-C1aB’s neuroprotective efficacy. Successful induction of the 
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MCAO procedure was first validated in a small cohort of animals (n=3) by monitoring changes of 
cerebral blood perfusion using a Laser Doppler Camera before, during, and after 50 min of MCAO. 
We found that compared with the pre-MCAO baseline (Fig. 6A), the procedure reliably reduced 
ipsilateral Doppler signal intensity by 50%, as compared to the contralateral, non-infarcted side 
(Fig. 6B). Removal of the suture for blood reperfusion achieved partial recovery of the cerebral 
blood flow after 15 min (Figs. 6C, 6D). 
The half-life for TAT-conjugated peptides is cargo-dependent and has been found to range 
from 1 h to as high as 18 h (Krosl et al., 2003; Bach et al., 2012; Wang et al., 2016). Our 2-photon 
data indicated that the FitC-tagged TAT-C1aB remained detectable above baseline in the CNS 
vasculature for at least 2 h after i.p. injection (Fig. 5B), suggesting a turnover rate within the range 
of comparable compounds. In vitro, the pro-apoptotic channel insertion process is known to take 
place by 3 h following an acute injury (Pal et al., 2006), while neuronal delayed rectifier currents 
have been observed to remain elevated 24 h after MCAO (Wu et al., 2015). Based on all of this 
information, we designed our experimental protocol to consist of two separate i.p. peptide 
injections, 1 and 6 h following the initiation of reperfusion (6 nmol/g per injection; Fig. 7A). 
Remarkably, in TAT-C1aB treated animals (n=7), 2,3,5-triphenyltetrazolium chloride (TTC) 
staining at 24 h after reperfusion revealed a 40% decrease in total brain infarct ratio compared to 
that of the TAT-SC (n=8) or saline-treated (n=10) animals (Figs. 7B, 7C). Analysis of individual 
2 mm coronal sections revealed that the reduction in infarct ratio provided by TAT-C1aB treatment 
was most prominent in the central infarct area (Fig. 7D). Of note, a ~13% increase in MCAO-
induced ipsilateral swelling was observed in all animal groups, regardless of the presence or 
absence of the peptide treatments.  That is, ipsilateral swelling was nearly identical in all three 
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treatment groups (saline: 112.9 ± 1.7%, n=10; TAT-SC: 114.0 ± 3.5%, n=8; TAT-C1aB: 115.2 ± 
2.2%, n=7; One-way ANOVA p=0.7811). 
We next evaluated the extent of neurological deficit amelioration provided by TAT-C1aB’s 
in vivo neuroprotection. In preliminary studies, animals treated with 50 min MCAO had an overall 
survival rate of 38.5% by 2 weeks (TAT-C1aB 42.9% n=3/7; TAT-SC 33.3%, n=2/6; Fisher’s 
exact test, NS), making it difficult to adequately assess behavioral deficits over time. By reducing 
the ischemia time to 40 min, the survival rate at 2 weeks was improved (TAT-C1aB 92.3%, 
n=12/13; TAT-SC 76.9%, n=10/13; Fisher’s exact test, NS). We thus evaluated the neurological 
score of animals exposed to 40 min MCAO and treated with either TAT-C1aB or TAT-SC, as 
described above (6 nmol/g, at 1 and 6 h following reperfusion), on an 8-points neurological deficit 
scale over 14 days (see Methods) (Xia et al., 2006). Consistent with the neuroprotection profile 
afforded by TAT-C1aB, a significant treatment group effect was observed in TAT-C1aB treated 
animals, which had an overall improved (lower) neurological deficits score when compared to 
TAT-SC treated mice (Fig. 7E). Notably, relatively similar numbers of animals (4/13 for TAT-
C1aB; 3/12 for TAT-SC) exhibited seizure-like behavior following MCAO. These in vivo results 
suggest that the degree of neuroprotection provided by TAT-C1aB is functionally significant.  
In addendum to the results of the original publication, we evaluated delayed injection times 
of TAT-C1aB at 3 and 6 hr. The results found that the treatment remained effective in reducing 





Figure 1. Generation of a Kv2.1-derived, STX1A-binding peptide sequence. 
A. Far-western assay of the proximal Kv2.1 C-terminus (C1a) region using 15 a.a. segments 
spanning residues Kv2.1 451-540, in overlapping one a.a. steps. Two peptides, highlighted in blue 
and red, flanked a region of high STX1A-binding. Error bars indicate mean ± SEM of signal 
intensity in 4 independent assays in the absence and presence (black bars) of 100 µM of the TAT-
containing derived STX1A-binding peptide described in (C) below. B. Representative peptide 
spot-array of the far-western experiment. C. Final sequences of the peptides used in the this study 
are shown. Orange sequence represents the cell-permeable HIV trans-activator of transcription 
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domain (TAT). Red sequence represents the STX1A-binding domain derived from Kv2.1. Green 




Figure 2. An illustration of the enhancement of Kv2.1 surface expression during neuronal apoptosis model 
and the protective mechanism of TAT-C1aB. 
A. In an untreated neuron facing lethal injury, the increased interaction between Kv2.1 and the 
SNARE protein STX1A through the Kv2.1 C1aB domain promotes channel incorporation into the 
plasma membrane (Pal et al., 2006). This enhances K+ efflux and enables apoptosis. B. A cell-
permeable peptide (TAT-C1aB) is created to contain the Kv2.1-derived STX1A-binding domain 
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C1aB. By competitively binding the Kv2.1-binding site on STX1A, TAT-C1aB provides 




Figure 3. TAT-C1aB prevents enhanced currents mediated by Kv2.1(S800E) and ameliorates TBOA-induced 
neuronal damage in vitro. 
A. Representative whole-cell K+ current traces and pooled means ± SEM of current densities 
recorded from CHO cells expressing WT Kv2.1 treated with vehicle (n = 11), 10 µM TAT-C1aB 
(n = 12), or 10 µM TAT-SC (n = 11) and CHO cells expressing Kv2.1(S800E) treated with vehicle 
(n = 11), 10 µM TAT-C1aB (n = 11), or 10 µM TAT-SC (n = 11). Overnight TAT-C1aB incubation 
significantly blocked the enhanced currents present in Kv2.1(S800E)-expressing cells (current 
density at +30 mV, vehicle vs TAT-C1aB: 267.2 ± 22.0 pA/pF vs 189.5 ± 19.6 Mean ± SEM; 
ANOVA/Dunnett, *p<0.05). Scale bar denotes 4nA/25ms. B. 100 µM TBOA treatment induces 
toxicity in GFP-expressing rat cortical neurons in vitro (28-32 DIV), but not in the presence of 1 
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µM TAT-C1aB. Scale bar denotes 10 µm. C. Lactate dehydrogenase (LDH) release, as an index 
of cell toxicity, was measured 24 h following TBOA treatment in 28-32 DIV rat cortical neuronal 
cultures. Co-incubation of 1 µM TAT-C1aB mitigated cellular damage of TBOA-treated neurons 
as indicated by decreased LDH release (1.31 ± 0.077 vs 2.45 ± 0.24 Mean ± SEM normalized 
colorimetric ratio; ANOVA/Dunnett, **p<0.01; n = 4 independent experiments, each performed 
in quadruplicate). Co-incubation with TAT-SC had no protective effects (n = 6 independent 




Figure 4.  TAT-C1aB does not influence NMDA-evoked Ca2+ responses in cortical neurons in vitro. 
A. Representative Ca2+ transient traces illustrating the average response of 50 rat cortical neurons 
from a single coverslip previously exposed to either (1 µM; 18 h) TAT-SC (black) or TAT-C1aB 
(gray). NMDA (30μM + 10μM glycine) was applied for 20 min following a 2 min baseline 
recording, and later washed for 5 min. B. Pooled means ± SEM (n=50 cells/coverslip; 3 coverslips 
per condition) show there is no significant difference in ΔF/Fo (0.69 ± 0.14 vs 0.58 ± 0.06; t-test, 
p>0.05) or area under the curve for the first 15 min of NMDA application (350.2 ± 59.6 vs 292.1 
± 41.1; t-test, p>0.05) between both peptide treatments.  
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Figure 5. Intraperitoneal TAT-C1aB administration reaches the brain vasculature. 
 
A. A representative montage of the in vivo two-photon imaging of FitC-tagged TAT-C1aB (TAT-
C1aB-FitC) fluorescent signals through a cranial window. TAT-C1aB-FitC was injected i.p. at 0 
min (6 nmol/g). An example region of interest (ROI; blood vessel) evaluated for fluorescence 
intensity over time is denoted by white square. Scale bar indicates 50 μm. B. Quantification of the 
2-photon imaging data. FitC fluorescence intensity was normalized to the pre-injection baseline. 
Error bars indicate SEM of mean signal intensity at the ROIs such as that shown in prior panels (n 
= 3). C. Injection of TAT-C1aB-FitC (6 nmol/g; i.p.), but not TAT-C1aB, increased fluorescence 
intensity throughout the brain nervous tissue at 1 h after injection. Animals were thoroughly, 
transcardially perfused before brain sections (2 mm) were obtained. Shown are, from left to right, 
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bright field images, fluorescence images, and heat maps generated from the fluorescent images. 
Note the higher signals present in section obtained from TAT-C1aB-FitC-labelled brains (n = 3).  
Scale bar indicates 2 mm. In addition, lower section is unpublished data showing that without the 




Figure 6.  In vivo validation of MCAO model. 
 
A-C. Laser sparkle Doppler images through the skull of an anesthetized mouse undergoing MCAO 
treatment. Images were taken at roughly 40 min pre (A), 15 min into MCAO (B), and 15 min post 
MCAO (C). Scale bar indicates relative signal intensity. D. Quantification of the mean Doppler 
signal intensity at each time point. A 50% decrease in Doppler signal intensity was observed during 
MCAO. Perfusion was partially recovered after suture was withdrawn. Bar graph indicates mean 
± SEM of % perfusion vs contralateral of each time point (n = 3; Two-way ANOVA, Sidak’s 




Figure 7. TAT-C1aB ameliorates ischemic stroke damage and improves neurological deficits in mice after 
MCAO. 
A. Timeline of the experiment, note TAT-C1aB was injected twice (i.p.) at 1 and 6 h following 
the initiation of reperfusion. B. Representative images of brain sections after TTC staining at 24 h 
after 50 min of MCAO injury. Injections of TAT-C1aB (i.p., 6 nmol/g, at 1+6 h reperfusion) 
seemed to drastically reduce infarct size. Scale bar indicates 5 mm. C. Quantification of total 
infarct ratio is shown (infarct ratio is defined as infarcted area/total area). The total infarct ratio of 
TAT-C1aB animals (n = 7) was significantly decreased compared with that of either saline (n = 
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10) or TAT-SC (n = 8) treated animals (0.12 ± 0.02 vs 0.20 ± 0.02 and 0.20 ± 0.02 mean ± SEM; 
ANOVA/Dunnett, **p < 0.01) at 24 h reperfusion. D. The majority of the neuroprotective actions 
of TAT-C1aB were located within the core infarct area. The infarct ratio at 4 mm (0.16 ± 0.02) 
and 6 mm (0.16 ± 0.02) coronal section of TAT-C1aB treated animals was significantly reduced 
compared to that of either vehicle (0.28 ± 0.02; 0.27 ± 0.03) and TAT-SC treated animals (0.29 ± 
0.03; 0.30 ± 0.02; ANOVA/Dunnett, **p<0.01).  E. Evaluation of neurological scores of mice 
following for 14 days following a 40 min MCAO using an 8-point neurological scoring system 
(see Methods). TAT-C1aB treated animals (n = 13) exhibited a significant improvement in overall 
neurological outcome when compared with the TAT-SC treated animals (n = 13; two-way 
ANOVA, *p = 0.0174). Error bars indicate mean ± SEM of neurological score.  Please note that 
treatments were randomized for all in vivo studies. Investigators performing surgeries, injection, 






Figure 8. TAT-C1aB significantly reduced infarct ratio after transient stroke with a delayed treatment 
regimen. 
A. Diagram of the experimental scheme in evaluating delayed TAT-C1aB treatment. Mice (24-
26g) received a delayed initial dose of TAT-C1aB or TAT-Scramble treatment (6 nmol/g) at 3h 
after 50m of transient ischemic stroke. The second dose was applied identically as previously at 
6h. B. TAT-C1aB significantly reduced the infarct ratio of mice brain after ischemic stroke 
compared with a scrambled control peptide (0.084±0.007 vs 0.11±0.009, n=8 and 7 respectively; 











Ischemic stroke is a leading cause of death worldwide (Thrift et al., 2016). Stroke survivors 
are often afflicted with permanent physical disabilities due to the loss of central neurons. While 
acute stroke causes almost immediate necrotic cell death in the ischemic core, programmed 
neuronal apoptosis in the penumbral region occurs for hours and can continue for several days 
(Bretón & Rodríguez, 2012). Unfortunately, over the past three decades, essentially all successful 
stroke treatments observed in preclinical studies have failed to demonstrate any therapeutic 
benefits in subsequent human trials (Kikuchi et al., 2014; Tymianski, 2014). Only recently, the 
excitotoxicity-ameliorating NA-1 (TAT-NR2B9c) has shown efficacy in a phase II clinical trial 
(Evaluating Neuroprotection in Aneurysm Coiling Therapy - ENACT), representing a potential 
novel approach to ischemic stroke treatment that is not a thrombolytic agent, and which, of 
relevance to the present study, is also a TAT-linked agent directed at interfering with an ion 
channel-associated lethal cascade (Hill et al., 2012). Nonetheless, no FDA approved stroke 
treatment yet exist that is intrinsically neuroprotective against delayed cell death (Tymianski, 
2013). The results presented here suggest that the inhibition of the apoptotic-specific functions of 
Kv2.1 is a potential novel approach to address this medical shortcoming.  
Recent findings have indirectly implicated the possible involvement of Kv2.1 antagonism 
as the underlying mechanism in other modes of neuroprotection. For instance, the FDA-approved 
anticonvulsant and KCNQ (Kv7) channel opener retigabine was shown to provide neuroprotection 
in an MCAO rodent model, an effect that was initially proposed to be mediated via regulation of 
neuronal excitability (Bierbower et al., 2015). Interestingly however, retigabine was also recently 
shown to inhibit Kv2.1 currents via a poorly reversible, open channel block mechanism, which 
could account for its neuroprotective actions (Stas et al., 2016). A similar mechanistic convergence 
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may also be present in an alternate model of Kv2.1-mediated neuronal apoptosis. Mutation of 
Kv2.1 N-terminal cysteine residue C73A to an alanine prevents cysteine-targeted oxidation of the 
channel, a step suggested to also be intimately linked to neuronal injury (Sesti, 2016; Yu et al., 
2016). Rodents carrying this mutation were found to show some protection in a model of traumatic 
brain injury (Yu et al., 2016), an injurious process with many parallel molecular cell death cascades 
to those observed in ischemic stroke (Quillinan et al., 2016). Interestingly, we have found that the 
C73A mutation also effectively prevents p38 phosphorylation of serine residue S800 and the 
associated K+ current elevation (He et al., 2015), thereby linking the oxidative and the membrane 
insertion processes of the channel during cell death cascades. Regardless, these observations offer 
support to the notion of suppressing enhanced Kv2.1 current after lethal injury as a potentially 
important and novel neuroprotective approach. 
The minimal STX1A binding domain within the Kv2.1 C-terminus is seemingly unique to 
this channel as we were unable to identify any other proteins containing this specific sequence via 
a BLAST search, except, as noted earlier, for a sequence within Kv2.2 containing 7 of the 9 a.a. 
found in Kv2.1 C1aB. In an overexpression system, Kv2.2 has indeed been shown to interact with 
STX1A, albeit in a manner different from that observed for Kv2.1 (Wolf-Goldberg et al., 2006). 
Specifically, Kv2.1/STX1A interactions are dramatically influenced by the presence of the 
additional SNARE protein SNAP-25, while this is not the case for Kv2.2 (Michaelevski et al., 
2003; Wolf-Goldberg et al., 2006).  We have previously found that enzymatic cleavage of either 
STX1A or SNAP-25 alone is sufficient to eliminate pro-apoptotic trafficking of Kv2.1 (Pal et al., 
2006), strongly suggesting that a formation of the STX1A/SNAP-25 SNARE complex is necessary 
for the observed enhanced currents. It is entirely possible that STX1A can indeed bind and 
influence Kv2.2 function in neurons, but given the various factors noted here, as well a lack of a 
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p38 phosphorylation site in Kv2.2 that is analogous to S800 in Kv2.1, we believe that the effects 
of our peptide reported in our study are mostly, if not perhaps exclusively, mediated through a 
Kv2.1-directed mechanism.     
As Kv2.1 is only expressed in the CNS in neurons (Murakoshi & Trimmer, 1999; Speca et 
al., 2014), TAT-C1aB may represent a unique and direct approach of suppressing cell death 
programs associated with neuronal enhanced K+ currents. Although traditional Kv blockers, such 
as tetraethylammonium and clofilium, have been shown to ameliorate ischemic damage (Wei et 
al., 2003), these drugs are also associated with increased vulnerability to epileptic seizures and 
ventricular tachycardia (Graham, 1950; Fueta & Avoli, 1993; Batey & Coker, 2002).  These off-
target effects make these molecules less than optimal candidates for stroke treatment. In contrast, 
we have observed no effects of TAT-C1aB on baseline currents, very similar to our previously 
reported actions of C1a overexpression and neuroprotection, both specifically targeting 
Kv2.1/STX1A interactions during apoptotic injury (McCord et al., 2014). In agreement with these 
findings, no increase in seizure-like behavior was observed in TAT-C1aB animals after ischemic 
stroke. The lack of reduction in post-stroke cerebral swelling also ruled out indirect protective 
mechanisms that could accompany ion flow manipulation in endothelial cells. Altogether, these 
data strongly suggest that TAT-C1aB targets a unique property of Kv2.1 that is intimately linked 
to a cell death process, and, importantly, it does not influence upstream processes such as NMDA 
receptor mediated Ca2+ responses. Along with the growing body of evidence indicating the 
significant involvement of pro-apoptotic Kv2.1 functions in many other neurodegenerative 
conditions (McCord & Aizenman, 2014; Shah & Aizenman, 2014; Yu et al., 2016), our 
observations may foreshadow the development of a new generation of highly robust 
neuroprotectants for human neurological conditions.  
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2.5 Materials and Methods 
Peptide spot array and far-western assay. Far-western protein binding affinity assays 
were performed as previously described (Brittain et al., 2011b). Peptide spot arrays (15 mers) 
spanning the proximal C-terminus residues 472-522 of rat Kv2.1 were constructed using the 
SPOTS-synthesis method. Standard 9-fluorenylmethoxy carbonyl (Fmoc) chemistry was used to 
synthesize the peptides and spot them onto nitrocellulose membranes pre-derivatized with a 
polyethylene glycerol spacer (Intavis AG). Fmoc protected and activated amino acids were spotted 
in 20-30 arrays on 150 mm by 100 mm membranes using an Intavis MultiPep robot. The 
nitrocellulose membrane containing the immobilized peptides was soaked in N-cyclohexyl-3-
aminopropanesulfonic acid (CAPS) buffer (10 mM CAPS, pH 11.0 with 20% vol/vol methanol) 
for 30 min, washed once with Tris-buffered 0.1% Tween 20 (TBST), and then blocked for 1 h at 
RT with gentle shaking in TBST containing 5% (mass/vol) non-fat milk and then incubated with 
enriched STX1A protein for 1 h at RT with gentle shaking. Next, the membrane was incubated in 
primary antibody for STX1A (Millipore Cat# AB5820-50UL, RRID: AB_2216165) for 2 h at RT 
with gentle shaking, followed by washing with TBST. Finally, the membrane was incubated in 
secondary antibody (goat anti-rabbit DyLight 800, Cat# 355571, Thermofisher) for 45 min, 
washed for 30 min in TBST and visualized by infrared fluorescence (Li-Cor). Four independent 
peptide spot arrays were utilized in this study.  A second set of membranes (n=4) was treated as 
above, but also in the presence of the identified peptide C1aB which had been coupled to TAT 
(TAT-C1aB; 100 uM; See Fig. 1).  Peptides were synthesized at >95% purity (theoretical 
molecular weight 2737.20 g/mol; GenScript), and were prepared in small aliquots with ultrapure 
water.  
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Electrophysiology. Whole-cell patch clamp experiments were carried out on CHO cells 
transfected with either WT Kv2.1 or Kv2.1(S800E), together with eGFP-expressing plasmid 
constructs. The S800E point mutation was performed in a prior study (Redman et al., 2007) and 
transfection was carried out as previously described (McCord et al., 2014). Briefly, CHO cells 
were plated on coverslips in 24-well plates at a density of 5.6 x 104 cells per well. Cells were 
treated for 3-4 h in serum-free medium with a total of 1.2 μL lipofectamine (Invitrogen) and 0.28 
μg DNA per well. Following transfection, cells were incubated with vehicle, 10 μM TAT-C1aB, 
or 10 μM scrambled control (TAT-SC) and maintained in F12 medium containing fetal bovine 
serum in 37°C and 5% CO2 for 24 h prior to recording. Current recordings were performed on 
eGFP-positive CHO cells using the whole-cell patch clamp configuration as described previously 
(McLaughlin et al., 2001). Borosilicate glass electrodes (3-4 MΩ; 1.5mm diameter; Sutter 
Instruments) were filled with internal solution composed of (mM): 100 K-Gluconate, 10 KCl, 1 
MgCl2, 1 CaCl2, 10 HEPES, 11 EGTA, 2.2 ATP, 0.33 GTP. The internal solution was further 
adjusted to pH 7.2, and to 280 mOsm with the addition of sucrose. The pH-adjusted (7.2) external 
solution was composed of the following (mM): 115 NaCl, 2.5 KCl, 2.0 MgCl2, 10 HEPES, 10 D-
glucose. Partial compensation (80%) for series resistance was performed for all recordings; 
currents were filtered at 2 kHz and digitized at 10 kHz (Digidata 1440A; Axon Instruments). 
Delayed rectifier currents were evoked with a series of 200 ms voltage steps to +80 mV from the 
holding potential of -80 mV in +10 mV increments. Measurements were performed with an 
Axopatch 200B amplifier and Clampex. Steady state current analysis was carried out at 180 ms, 
at the +30 mV voltage step relative to baseline current. Current density (pA/pF) was calculated by 
normalizing the current amplitude measurement to cell capacitance, an electrical determination of 
cell size. Recordings were carried out at room temperature (~25°C).  
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Cortical cultures, LDH Assay and Calcium Measurements. All animal protocols in this 
study were approved by the Institutional Animal Care and Use Committee of the University of 
Pittsburgh School of Medicine. Cortical neurons were prepared from embryonic day 16 (E16) rats 
of either sex as described previously (McCord et al., 2014). Pregnant donor rats (Charles River 
Laboratories) were euthanized by gradual CO2 inhalation, an American Veterinary Medical 
Association approved protocol (Leary et al., 2013). Cortices were dissociated with trypsin, and 
plated at 670,000 cells per well on glass coverslips in six-well plates as described in (Hartnett et 
al., 1997). Non-neuronal cell proliferation was inhibited with 1-2 μM cytosine arabinoside. DL-
threo-beta-benzyloxaspartate (TBOA; Tocris) excitotoxicity assays were carried out on 28-35 DIV 
cultures. Coverslips were transferred into 24-well plates containing 10 mM HEPES-supplemented 
MEM without phenol red. On each individual plate, coverslips were treated with vehicle or 100 
μM TBOA and 0, 0.3, or 1 μM of either TAT-C1aB or TAT-SC at 37°C and incubated in 5% 
CO2 for 24 h. Following this, external medium was collected for LDH colorimetric measurements 
using a toxicity kit (Sigma-Aldrich), as previously described (Aras et al., 2001). Each experiment 
contained 4 replicates of 6 conditions, including 3 control and 3 TBOA treatment groups; peptide 
treatment groups (TAT-C1aB, TAT-SC) were evaluated in separate experiments. Cell toxicity was 
quantified as the LDH ratio of TBOA-treated over no TBOA control values within each 
experiment. For direct visualization of individual neurons in a similar set of assays, eGFP protein 
transfection was carried out using Lipofectamine 2000 (Invitrogen) as previously described 
(McCord et al., 2014). Cells were imaged at 60x using an A-1 confocal microscope (Nikon). 
Intracellular Ca2+ measurements were performed essentially as previously described 
(Aizenman et al., 1990; Reynolds et al., 1990) on the same cortical culture preparations as above, 
but with 20 DIV cells plated on MatTek glass bottom 35 mm culture dishes.  At this developmental 
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stage, neurons robustly express both GluN2A and GluN2B subunits of the NMDA receptor (Sinor 
et al., 2000).  Prior to recordings, cultures were incubated overnight with 1 µM of either TAT-
C1aB or TAT-SC.  These treatments were removed just prior to the Ca2+ measurements.  For 
recordings, neurons were incubated with the fluorescent Ca2+ indicator Fura-2 AM ester (5 μM; 
Invitrogen) with 0.02% Pluronic F-127 (Invitrogen) for 1 h at 37°C. Culture dishes were then 
mounted on an inverted microscope stage (Olympus) and continuously perfused with a 10 mM 
HEPES buffered normal salt solution. Perfusion rate (5 mL/min) was controlled with a gravity 
flow and a rapid-switching local perfusion system (Warner Instruments). Firmly attached, 
refractile cells were identified as regions of interest (50 cells/coverslip; 3 coverslips per condition). 
A ratio of fluorescence emission (F) at 510 nm in response to excitations at 340 and 380 nm was 
acquired at 1 Hz (Lambda DG-4 and 10-B SmartShutter; Sutter Instruments) via camera (ORCA-
ER; Hamamatsu Corporation) and saved to a computer using HCImage (Hamamatsu Corporation). 
Baseline Ca2+ signals were recorded for 2 min prior to a 20 min application of NMDA (30 µM + 
10 µM glycine) followed by a 5 min washout period.  Peak increases in intracellular calcium 
concentration were measured by calculating ΔF/Fo, (ΔF=peak fluorescence, Fo=average signal 
across 2 min baseline period).  The area under the response for the first 15 min of NMDA 
application was also calculated.   
 
Fluorescently-labeled peptide brain imaging. For 2-photon imaging of TAT-C1aB-FitC 
in cortical vasculature, a cranial window was opened over the temporal lobe area in head-fixed 
young adult mice under isoflurane anesthesia (induction: 3% in oxygen, maintenance: 1.5% in 
oxygen; Butler Schein). Mode-locked infrared laser light (940 nm, 100-200 mW intensity at the 
back focal plane of the objective, MaiTai HP, Newport) was delivered through a galvanometer-
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based scanning 2-photon microscope (Scientifica) controlled with scanimage (Pologruto et al., 
2003), using a 40X, 0.8 NA objective (Olympus). After obtaining a stable imaging location (field 
of view 145 m x 145 m, 100-200 µm deep from the cortical surface), a single i.p. injection of 
TAT-C1aB-FitC (6 nmol/g) was administered to the animal. We imaged FitC fluorescence 
emission with a photomultiplier tube (PMT) and a green emission filter (FF03-525/50, Semrock) 
at 5 to 10 minute intervals for 15 minutes before and two hours after i.p. injection. The laser power 
and PMT voltage remained constant throughout the imaging session. Quantification of ROI signal 
intensity was evaluated by Image J analysis software (NIH). 
To confirm blood brain barrier permeability of the TAT-linked peptide, mice were 
thoroughly perfused with ice-cold saline 1 h after i.p. injection of either TAT-C1aB or TAT-C1aB-
FitC (6 nmol/g).  Brains were quickly removed, sectioned into 2 mm slices and imaged using an 
Olympus MVX10 microscope with a SPOT RT3 camera. TAT-C1aB and TAT-C1aB-FitC-
labelled brains were imaged sequentially with identical camera settings. Generation of the 8-bit 
fluorescence signal heat map was performed using the ImageJ plugin HeatMap Histogram 
(http://www.samuelpean.com/heatmap-from-stack/). 
In vivo cerebral blood flow measurements. Cerebral blood flow was monitored using a 
two-dimensional laser speckle contrast analysis system (PeriCam PSI High Resolution with 
PIMSoft; Perimed). Anesthesia was induced by 3%, and maintained at 1.5% isoflurane (Butler 
Schein) in 3:1 NO:O2 gas mixture using a vaporizer (General Anesthetic Service). Throughout the 
experimental procedure, rectal temperature was maintained between 36.5 and 37.0°C using a 
feedback-controlled heating system (PhysioSuite). The skull of the animal is secured in a 
stereotactic frame (David Kopf Instruments). A midline incision was made in the scalp and the 
skull surface was cleaned with sterile normal saline. At 40 min prior to MCAO, 15 min into 
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MCAO, and 15 min after reperfusion, blood perfusion images were taken with a charged-coupled 
device camera placed 10 cm above the skull. Raw speckle images were taken in a 1.6 cm x 1.4 cm 
field at 19 frames/second, 57 frames averaging, with the resolution of 0.02 mm. Five consecutive 
images at each time point per animal were averaged for analysis using oval-shaped regions of 
interest (ROI) covering the frontal and parietal bone plates of the ipsi- and contra-lateral sides. 
Percent signal intensity was calculated by comparing the ipsilateral side mean signal intensity to 
that of the contralateral side at each time point. 
MCAO procedure. Each cohort of young adult mice (ages 8-10 wks, male, 24-29g; 
Jackson Laboratory) were randomized to each group to account for possible confounding factors 
in the experimental order and body weight on the day of the surgery. However, as body weight did 
not vary that much we were able to use the same model/thickness of single-use silicon-coated 
sutures for all animals (# 602212PK10; Doccol Corporation). The suture was advanced from the 
junction of the external and the common carotid artery into the internal carotid artery for ~9 mm 
or until resistance was felt. The suture was secured in this position for the duration of the ischemia 
time (40/50 min). Mice were anesthetized with isoflurane and maintained at physiological body 
temperature as described above. Animals were only anesthetized during the surgery. Researchers 
performing MCAO (C-Y.Y), drug injections (C-Y.Y.), neurological assessment (A.M.B.), and 
quantitative analysis of the infarct size (E.A.) were all blinded to the treatment groups. Treatments 
(saline, TAT-C1aB or TAT-SC) had been previously randomized by an additional experimenter 
(K.A.H., A.M.B.). 
Infarct Ratio Measurements. For quantification of the infarct area, whole brains were 
extracted from each animal and dissected into 2 mm sections before being stained with 2,3,5-
triphenyltetrazolium (TTC; Sigma-Aldrich) with the optimal staining protocol specifications 
 50 
described previously (Joshi et al., 2004): 0.05% TTC in PBS, at 37°C, for 30 min. Brain slices 
were scanned after TTC staining and the infract ratio was measured as the total or section infarct 
area/total area. Infarct size was measured through Image J analysis software. Percent swelling was 
calculated as (Ipsilateral volume/Contra lateral volume) x 100%.  
Neurological Testing. Neurological deficits were assessed on days 1, 2, 3, 5, 7, 10, and 14 
following MCAO surgery. Mice were evaluated by a blinded experimenter on an 8-point scale as 
described previously (Xia et al., 2006), adapted for left side MCAO. Briefly, 0 = no neurological 
deficit; 1 = right forelimb flexion when suspended the tail or failure to extend left forepaw fully; 
2 = right shoulder adduction when suspended by tail; 3 = reduced resistance to lateral push towards 
the right; 4 = spontaneous movement in all directions with circling to the right exhibited only if 
pulled by tail; 5 = circle or walk spontaneously only to the right; 6 = walk only when stimulated; 
7 = no response to stimulation; 8 = stroke-related death. 
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3.0 Defining the Kv2.1-syntaxin molecular interaction identifies a novel class of 
small molecule neuroprotectants 
3.1 Section Summary 
The neuronal cell death-promoting loss of cytoplasmic K+ following injury is mediated by 
an increase of Kv2.1 potassium channels in the plasma membrane. This phenomenon relies on 
Kv2.1 binding to syntaxin 1A via 9 amino acids within the channel intrinsically disordered C-
terminus. Preventing this interaction with a cell and blood brain barrier-permeant peptide is 
neuroprotective in an in vivo stroke model. Here, a rational approach was applied to define the key 
molecular interactions between syntaxin and Kv2.1, some of which are shared with Mammalian 
UNCoordinated-18 (munc18). Armed with this information, we discovered the first small 
molecule Kv2.1-syntaxin binding inhibitor (cpd5) that improves cortical neuron survival by 
suppressing the SNARE-dependent enhancement of Kv2.1-mediated currents following 
excitotoxic injury. We validated that cpd5 selectively displaces Kv2.1 syntaxin-binding peptides 
and, at higher concentrations, munc18, without affecting either synaptic or neuronal intrinsic 
properties in brain tissue slices at neuroprotective concentrations. Collectively, our findings reveal 
insights into the role of syntaxin in neuronal cell death and validate an important, novel target for 
neuroprotection. 
Significance Statement. Enhanced Kv2.1-syntaxin interaction precedes the neuronal cell 
death-promoting loss of cytosolic K+ in many neurodegenerative conditions. The work here 
characterizes the interaction of the disordered C-terminus of Kv2.1 at a molecular level and further 
translates these findings to discover a first-in-class small molecule with neuroprotective properties. 
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In doing so, we demonstrated a rational drug discovery workflow that can elucidate protein-protein 
interactions involving highly unstructured domains. 
3.2 Introduction 
Therapeutic options to prevent, halt, or ameliorate neurodegenerative disorders remain 
critical areas of unmet medical need in spite of more than three decades of aggressive research 
efforts (Gribkoff & Kaczmarek, 2017; Editorial, 2018). Central to this challenge is the fact that 
many neurological diseases are driven by proteins with highly flexible and unstructured domains 
that bind multiple partners, making both their mechanistic characterization and their 
pharmacological targeting exceedingly difficult (Uversky, 2015). Indeed, these intrinsically 
disordered unstructured domains are quite common amongst various disease-associated 
membrane-bound receptors and ion channels, especially in their regulatory cytoplasmic regions 
(Kjaergaard & Kragelund, 2017). One such protein is the delayed rectifier potassium channel 
Kv2.1, which enables a well-characterized neuronal cell death cascade through its cytoplasmic C-
terminus domain (Shah & Aizenman, 2014). In the current study, we focus on a key interactor of 
the Kv2.1 C-terminus, namely syntaxin 1A (syntaxin), to further unveil the molecular mechanisms 
involved in Kv2.1-dependent neurodegeneration and to pursue a novel translational strategy. 
Following an injurious stimulus, Kv2.1-mediated regulation of intracellular K+ is a critical 
convergent factor in neuronal cell death programs. At normal physiological concentrations, 
cytoplasmic K+ suppresses the catalytic activity of several proteases and nucleases linked to 
cellular pathology (Hughes & Cidlowski, 1999). Enhanced K+ efflux in injured neurons, however, 
facilitates rapid execution of cell death cascades (Yu et al., 1997; Yu, 2003). Kv2.1 mediates this 
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cell death-promoting cytoplasmic K+ loss in a number of neuronal subtypes including cortical 
neurons (Pal et al., 2003), hippocampal pyramidal neurons (Chi & Xu, 2000; Wu et al., 2015), 
midbrain dopaminergic neurons (Redman et al., 2006), and cerebellar granule cells (Jiao et al., 
2007). The Kv2.1-dependent cell death pathway is normally initiated by the oxidative liberation 
of zinc from intracellular metal-binding proteins (Aizenman et al., 2000), leading to the sequential 
phosphorylation of Kv2.1 residues Y124 and S800 by Src and p38 kinases, respectively (Redman 
et al., 2007; Redman et al., 2009; He et al., 2015). The dual phosphorylation of the channel 
enhances its interaction with syntaxin and increases its surface expression, inducing the subsequent 
loss of intracellular K+ (Pal et al., 2003; Pal et al., 2006; Redman et al., 2006; McCord & 
Aizenman, 2013; Shah & Aizenman, 2014).  
The Kv2.1 domain responsible for the interaction with syntaxin is located within the 
intrinsically disordered Kv2.1 proximal cytosolic C-terminal, originally termed C1a by Gaisano, 
Lotan, and co-workers (Leung et al., 2003; Singer-Lahat et al., 2007; Singer-Lahat et al., 2008). 
Overexpression of a fragment containing residues 441-522 within the C1a region (Kv2.1 rat 
sequence; NCBI accession # NP_037318.1) is sufficient to inhibit the injury-induced plasma 
membrane insertion of Kv2.1 channels in neurons and provide neuroprotection in vitro (McCord 
et al., 2014). Recently, we further narrowed down the amino acid sequence within C1a to 9 
residues, namely H1LSPNKWKW9 (C1aB; from N- to C-terminus, corresponding to Kv2.1 
residues 478-486 in rat, and 482-490 in mouse and humans; Accession #s NP_032446.2 and 
NP_004966.1, respectively). Most importantly, blocking the interaction between Kv2.1 and 
syntaxin using a blood-brain-barrier permeable conjugated peptide (TAT-C1aB) effectively 
ameliorates acute neuronal ischemic injury, limiting infarct damage and improving neurological 
function in vivo (Yeh et al., 2017).  
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The chemical disruption of protein-protein interactions involving intrinsically disordered 
regions such as the Kv2.1 C-terminus is an unique challenge for pharmaceutical intervention, as 
these domains not only undergo structural rearrangements upon binding but also involve 
selectively promiscuous sites that regulate multiple interactions (Pabon & Camacho, 2017). This 
task is further hindered by the fact that the syntaxin site for Kv2.1 binding has not, heretofore, 
been resolved. To address these challenges, we developed a rational approach that combines 
molecular modeling, biophysics, and cell-based experimental validations. This approach led us to 
elucidate the molecular actors essential to the Kv2.1-syntaxin interaction, predicting it to exist 
within the complex binding site previously resolved for the co-crystal structure between syntaxin 
and Mammalian UNCoordinated 18 (munc18), a critical component of exocytotic processes 
(Toonen & Verhage, 2007). We then began the translation of these results with a virtual screening 
of small molecule libraries with the goal of inhibiting the Kv2.1-syntaxin interaction while 
minimally interfering with munc18 function. This process led to the identification of a first-in-
class protein-protein inhibitor and lead compound that can prevent neuronal injury. These findings 
reveal mechanistic insights of syntaxin’s role in cell death functions and validate a novel target for 
the development of neuroprotective therapeutics. 
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3.3 Results 
3.3.1  Structural modeling of Kv2.1 C1aB H1LSPNKWKW9 peptide and its interactions with 
syntaxin  
Syntaxin binding to the C1a region of Kv2.1 is largely restricted to within a nine amino 
acid sequence of the channel we previously defined as C1aB (H1LSPNKWKW9). We had observed 
a rapid drop-off in syntaxin binding when C-terminal C1aB residues are removed in a large avidity 
panel of Kv2.1 C1a-derived 15-mer peptides (Yeh et al., 2017), alerting us to the possibility that 
the essential interactions of the syntaxin binding domain could be further refined. We thus carried 
out molecular dynamics simulations of Kv2.1-derived peptides containing partial or complete 
C1aB sequences to analyze the stability of these peptides. Figures 9A and 9B show both a 
representative snapshot and the conformational ensembles entailed by the C1aB K6W7 sequence 
motif for four different peptides. Two of the strongest syntaxin-binding peptides (Yeh et al., 2017) 
(pep-22 and pep-28) consistently show a fully solvent-exposed W7 residue with the preceding K6 
in the opposite trans direction. In contrast, the two weakest syntaxin-binding peptides (pep-20 and 
pep-21) show the increasing occlusion of W7 by interactions with K6 side chain upon deletion of 
either the K8W9 residues or just the W9 from the corresponding C1aB sequence. This is evident 
in the increasing probability of K6 to be in the interfering cis positions when the two anchoring 
residues are removed in the weakly binding peptides (Fig. 9B). The observed stability of the free 
W7 in strongly binding peptides suggests that this residue plays a critical role in the recognition 
of syntaxin, whereas deletion of W9 could have an impact in binding affinity by inducing the 
occlusion of W7 but, as suggested by our previous work (Yeh et al., 2017), the shorter peptide 
would still able to bind the SNARE protein to some extent. 
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3.3.2  The Kv2.1 C1aB W7 syntaxin-binding structural motif is shared with                                                                                           
munc18 W28 
The co-crystal structure of the closed form of syntaxin and Mammalian UNCoordinated 18 
(munc18) (PDB code 4JEH (Toonen & Verhage, 2007; Burkhardt et al., 2008)), a known 
modulator of synaptic transmission that is essential for the proper assembly of syntaxin with other 
SNARE components (Jiao et al., 2018), is stabilized by multiple hydrogen bonds and non-polar 
interactions encompassing both the syntaxin regulatory Habc and core SNARE H3 domains. This 
includes a specificity determinant aromatic stacking between munc18 W28 and syntaxin F34, on 
the first helix of the Habc domain (Fig. 10A). Structural similarities between our simulated C1a 
peptides (Fig. 9A) and the corresponding motif in munc18 bound to syntaxin (Fig. 9C), which also 
has an adjacent lysine residue (K29), led us to perform an unbiased docking of a C1aB peptide on 
syntaxin’s binding surface with munc18 (PDB 4JEH). Using the software SMINA (Koes et al., 
2013) with default settings, we obtained the C1aB docked pose shown in Fig. 10B. 
3.3.3  Experimental validation of C1aB/syntaxin interactions 
All the intermolecular interactions in our C1aB/syntaxin binding model (see detailed view 
in Fig. 10D) are not only chemically favorable but are also strikingly consistent with an alanine 
scan mutagenesis of individual C1aB amino acids in a syntaxin-binding peptide array assay (Fig. 
9D). In particular: (i) W7 stacking interaction with syntaxin F34 is eliminated in W7A, but 
nonpolar contacts remain; (ii) W9 hydrophobic contacts with syntaxin I115 are absent in W9A, 
thereby significantly decreasing binding affinity; (iii) C1aB K6 backbone, whose side chain is 
opposite to W7, interacts via hydrogen bonds with Q119, a property retained in K6A; (iv) L2 is 
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buried in a hydrophobic pocket formed by syntaxin’s L123, K126 and T122, and, thus, the 
hydrophobic side chain present in L2A may somewhat decrease binding affinity; finally, (v) C1a 
H1 hydrogen bonds with T122 and D231 are expected to be replaced in H1A, with D231 bonding 
to the free amine group in the N-terminus of the peptide.  
It is noteworthy that interactions equivalent to those seen in our C1aB model are also 
observed in the munc18 and syntaxin co-crystal (Fig. 10C), further supporting the accuracy of our 
proposed model. Specifically, and as shown in detailed contacts of munc18 and syntaxin in Fig. 
10C, (i) munc18 W28 stacking with syntaxin F34, with the nearby K29 pointing in the opposite 
direction, is analogous to the arrangement of C1aB W7, (ii) munc18 T56 and I57 contact syntaxin 
I115, analogous to the interactions of C1aB W9; (iii) the crystal water in the munc18 binding 
interface, fully coordinated by syntaxin Q119, T122, R41, together with the munc18 M51 
backbone, is reshaped into a non-polar pocket in syntaxin, burying C1aB L2; and, finally, (iv) 
munc18 T48 hydrogen bond with syntaxin D231 is mimicked by C1aB H1. Taken together, 
unbiased docking of C1aB peptide fully rationalizes the alanine scanning, where W7 aromatic 
stacking with syntaxin’s F34 and the burial of L2 in a non-polar pocket are the specificity 
determinant interactions of Kv2.1 C1aB with syntaxin. Notably, deletion of either of these residues 
in our C1a-derived 15-mer peptides obliterate binding (Yeh et al., 2017) (see, also, Fig. 13). 
3.3.4  Virtual screening of Kv2.1/syntaxin inhibitors identifies six small molecule candidates 
Leveraging the aforementioned structural insights, we performed a small molecule virtual 
screening with the goal of inhibiting C1aB protein-protein interaction with syntaxin. To do this, 
we designed pharmacophore models and use the search engine ZINCPharmer (Koes & Camacho, 
2012) to screen 26+ million commercially available compounds present in the ZINC database 
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(Irwin & Shoichet, 2005). Models were designed to include a ring-stacking interaction with F34 
and also match different combinations of hydrogen bonds formed by crystal water 315 in PDB 
4JEH with syntaxin’s Q119, T122 and R41 (Fig. 10A, 10C). After the primary screening based on 
these pharmacophores, compounds matching our design underwent an all atom optimization (Ye 
et al., 2016), resulting in the six molecules shown in Fig. 11A that were selected for in vitro 
experimental testing. Fig. 15A, 15B shows the list and chemical structures of these selected 
compounds, abbreviated as cpd1 to cpd6. 
3.3.5  Cell-based screening of small molecule cpd5 reveals neuroprotective properties 
To determine whether cpd1-6 could recapitulate the previously described biological effects 
of C1a and TAT-C1aB (McCord et al., 2014; Yeh et al., 2017), we evaluated them in vitro first for 
intrinsic toxicity and then for neuroprotective actions in rat cultured cortical neurons. We found 
that cpd1 did not readily dissolve at a reasonable concentration using a variety of solvents. We 
also observed that cpd2 was at times neurotoxic after 24 hr incubation at 10 μM (Fig. 15C), 
quantified as a significant increase in extracellular lactate dehydrogenase (LDH) above baseline 
(relative toxicity), a sign of cellular damage (Aras et al., 2008). Therefore, cp1 and cpd2 were 
excluded from further studies. The remaining four compounds were not neurotoxic at 
concentrations as high as 10 µM (Fig. 15C, 15D). We next examined whether these molecules 
could provide neuroprotection against overnight applications of threo-beta-Benzyloxyaspartate 
(TBOA; 75 µM), a non-selective glutamate reuptake inhibitor (Shimamoto et al., 1998). TBOA 
induces relatively slow (overnight) NMDA receptor-mediated excitotoxicity characterized by 
Kv2.1-dependent cell death in our cultures (Yeh et al., 2017; Justice et al., 2018). We found that 
pre-treatment (1 hr) and co-incubation with 10 µM cpd5 (3-[3-(1,3-benzothiazol-2-yl)phenyl]-1-
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[(3,4-dimethoxyphenyl)methyl]urea; molport-009-741-732) significantly diminished TBOA 
toxicity, an effect nearly identical to the actions of 1 µM TAT-C1aB treatment (Fig. 12A, 12B). 
In phase contrast imaging, we observed that TBOA treatment reduces the number of phase-bright, 
healthy neurons, which was ameliorated with the co-treatment of cpd5 (Fig. 12A left). To better 
visualize this result, we transfected neurons with eGFP prior to treatment and confirmed that 
TBOA treatment causes significant cellular damage, which is ameliorated in cells co-treated with 
cpd5 (Fig. 12A right). In contrast to cpd5, cpds 3,4 and 6 did not afford any measurable 
neuroprotection and thus were also excluded from further studies (Fig. 15E).  
The docked pose of cpd5 with syntaxin, shown in Fig. 11A, 11B, recapitulates all the 
interactions that we found to be essential for C1aB binding to syntaxin. Namely, it shows an 
optimal stacking with F34 through the benzothiazole ring, hydrophobic contact between the 
benzene ring and V37, hydrogen bonds with A41, N119, and T122 all established by the munc18 
crystal water and essential for C1aB L2 binding to syntaxin, and the interaction of the veratrole 
group and K126. This fully rationalizes cpd5 as potentially effective in disrupting the 
Kv2.1/syntaxin interaction. Mechanistically, dispersing somatodendritic Kv2.1 clusters has also 
been shown to be a viable approach to prevent the increase of death-inducing K+ currents (Justice 
et al., 2017). To rule out that cpd5 is providing neuroprotection by declustering Kv2.1, we 
transfected neurons with Kv2.1-eGFP and evaluated their clustering status after 24 hr exactly as 
previously described (Justice et al., 2017). We found no significant effect of 24 hr 10 µM cpd5 
treatment on Kv2.1 clusters (Fig. 15F). This finding is consistent with the previously observed 
lack of declustering properties of Kv2.1 C1a over-expression in cortical neurons (Justice et al., 
2017), strongly suggesting that inhibiting Kv2.1/syntaxin interaction subdues the translocation of 
new Kv2.1 channels to the membrane. 
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3.3.6  Cpd5 suppresses cell death-enabling K+ currents 
The hallmark of Kv2.1-facilitated neuronal cell death is the accompanying large increase 
in delayed rectifier K+ currents as the result of syntaxin-dependent de novo Kv2.1 channel insertion 
in the plasma membrane (Pal et al., 2006). We previously showed plasmid-mediated 
overexpression of C1a or the use of the TAT-C1aB peptide prevents the Kv2.1-mediated current 
surge (McCord et al., 2014; Yeh et al., 2017). To determine whether cpd5 achieves similar 
inhibition of current enhancement, we carried out whole cell patch clamp recordings of rat cortical 
neurons in vitro after co-incubation with TBOA (50 µM for 2 hr followed by a 2 hr wash period), 
a treatment that we have shown to cause the canonical Kv2.1 current increase (Justice et al., 2018). 
In strong agreement with our neuroprotection assays, we found that cpd5 (10 µM) pre-loading (1 
hr) and co-treatment with TBOA effectively suppressed the post-injury enhancement of delayed 
rectifier K+ currents in neurons to levels comparable to uninjured neurons (Fig. 12C striped red 
bar). Importantly, we found no significant effects of cpd5 incubation alone on basal K+ currents 
(Fig. 12C red bar), strongly suggesting that the pre-existing membrane-bound channels and the 
normal trafficking of the channel during the 5 hours total duration of cpd5 incubation are 
unaffected by the drug. This is consistent with previous findings in cells expressing the C1a 
fragment or treated with TAT-C1aB (McCord et al., 2014; Yeh et al., 2017). Most significantly, 
the inhibition of the injury-enhanced currents, a syntaxin-dependent process (Pal et al., 2006), 
strongly points to an on-target action of cpd5.   
Because NMDA receptors mediate the neurotoxicity elicited by glutamate reuptake 
inhibitors (Blitzblau et al., 1996), we evaluated whether cpd5 inhibited NMDA-evoked Ca2+ 
response, a major component of acute excitotoxicity (Choi, 1987; Sattler & Tymianski, 2001). We 
thus performed Fura-2 ratiometric Ca2+ imaging in cultured neurons during NMDA (30 µM with 
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10 µM glycine) exposure, noting a lack of any effect of concurrently-administrated cpd5 (10 µM) 
on NMDA-evoked Ca2+ responses (Fig. 12D). This strongly indicates that the aforementioned 
neuroprotective actions of cpd5 likely did not occur as a result of direct interference with the 
upstream components of the excitotoxic cascade. Rather, these findings are evidence that cpd5, 
like TAT-C1aB, provide neuroprotection against TBOA-induced excitotoxicity specifically by 
preventing the expression of enhanced Kv2.1-mediated K+ currents.  
3.3.7  Cpd5 is a first-in-class inhibitor of Kv2.1 binding to syntaxin 
The docked model of cpd5 shown in Fig. 11B predicts cpd5 to strongly compete with 
essential interactions of C1aB and syntaxin. In addition, since munc18 binds to both the core 
SNARE domain and the N-terminal region of the closed conformation syntaxin (Fig. 10A) (Misura 
et al., 2000), we expected cpd5 to displace C1aB more effectively than displacing munc18. To 
confirm this prediction, we first performed a peptide array binding assay and observed that cpd5 
(100 µM) significantly reduced binding between syntaxin and all of the previously identified (Yeh 
et al., 2017) Kv2.1 C1a-derived syntaxin-binding peptides (Fig. 13). Of note, inhibition occurred 
for all the peptides that contained the predicted stacking interaction between C1aB W7 and 
syntaxin F34, as well as C1aB L2. We also gauge the specificity of cpd5 by noting that it had a 
negligible effect on any of the remaining non-specific or weak reads. To evaluate the potency of 
cpd5, we measured concentration-dependent inhibition of syntaxin binding to peptides 22 to 28, 
which contain the full C1aB sequence, obtaining a fitted IC50 of 5.5 µM with a maximum 
effectiveness of up to ~75% binding displacement by 100 µM Cpd5 (Fig. 13 Inset, fitted curve of 
averaged data). Higher concentrations of Cpd5 could not be tested due to solubility issues. Next, 
we performed a co-immunoprecipitation assay of syntaxin and munc18 in transfected HEK293 
 62 
cells incubated in various concentrations of cpd5. Consistent with our prediction, we found that 
cpd5, at both 30 and 100 µM, robustly disrupts binding between munc18 and syntaxin (Fig. 16A); 
the specificity of the antibodies used in this experiment was also confirmed (Fig. 16B). Of note, 
munc18 was not displaced by cpd5 at the neuroprotective concentration of 10 µM, which, as 
evident above, can displace C1aB-containing peptides from syntaxin. Together, these results 
demonstrate that the observed neuroprotective actions of cpd5 are likely due to the inhibition of 
the C1a region of Kv2.1 binding to syntaxin. 
3.3.8  Cpd5 does not alter either synaptic or intrinsic properties of neurons 
Loss of munc18 function blocks neurotransmitter release, causing munc18-/- animals to 
suffer paralysis and rapid global neurodegeneration after birth (Verhage et al., 2000; Weimer et 
al., 2003). Despite cpd5’s overlapping syntaxin binding site with that of munc18, we did not find 
it to be neurotoxic in vitro at concentrations as high as 30 μM (Fig. 15D). However, it remained 
necessary to evaluate the possibility of cpd5 causing non-specific effects on neuronal synaptic and 
intrinsic properties. For this purpose, we evaluated the effects of 10 μM cpd5 on the synaptic and 
intrinsic properties of two distinct populations of projection neurons in the mouse auditory cortex: 
the layer 2/3 corticocallosal neurons projecting to the contralateral auditory cortex and the layer 
5B corticocollicular neurons projecting to the ipsilateral inferior colliculus (Joshi et al., 2015; Joshi 
et al., 2016). In addition to being guided by anatomical landmarks such as the rhinal fissure and 
the hippocampus anatomy to locate the auditory cortex, we injected green retrograde fluorospheres 
in the contralateral cortex and red retrograde fluorospheres in the ipsilateral inferior colliculus to 
label the layer 2/3 corticocallosal and layer 5B corticocollicular neuronal populations respectively 
(Fig. 14A Left). We have previously confirmed that retrogradedly labeled layer 2/3 corticocallosal 
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and layer 5B corticocollicular neurons in this manner consistently overlay with the functionally 
localized auditory cortex (Joshi et al., 2015; Joshi et al., 2016). Local stimulations to layer 2/3 
were used to evoke EPSCs in retrogradely labeled layer 2/3 corticocallosal neurons (Fig. 14A 
Right). Application of cpd5 (10 μM) caused no significant differences in the amplitude of 
AMPAR-mediated excitatory post-synaptic currents evoked in these cells (Fig. 14B-D). Next, we 
examined the effects of cpd5 (10 μM) on the intrinsic properties of labeled layer 5B 
corticocollicular neurons (Fig. 17A). Cpd5 did not have any effect on resting membrane potential 
(Fig. 17B), input resistance (Fig. 17C), and HCN channel-mediated (Ih) sag potential (Fig. 17D). 
Action potential threshold (Fig. 17E), width (Fig. 17F), and firing rates (Fig. 17G) were also 
unchanged by the cpd5 treatment. These results demonstrate that cpd5 does not affect either the 
synaptic properties of layer 2/3 corticocallosal neurons or the intrinsic properties of layer 5B 
corticocollicular neurons in the mouse auditory cortex, consistent with the fact that the drug does 




Figure 9. Structural analysis and validation of Kv2.1 syntaxin-binding peptides. 
A, Representative molecular dynamics snapshots of four Kv2.1-derived peptides labeled with their 
relative binding strength (Yeh et al., 2017). From first row down, Kv2.1 peptides sequences 
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containing up to: W7 (pep-20), K8 (pep-21), and the entire C1aB region (pep-22, pep-28). B, 
Assembly of 100 snapshots of K6W7 from the corresponding peptides sampled every 4 ns after 
100 ns of equilibration. Snapshots were aligned on W7 (grey) with K6 sampling both possibly 
interfering cis (red) and non-interfering trans (blue) conformations. The W7s of the strong binding 
peptides (pep-22 and pep-28) were solvent exposed and ready to make contacts with interacting 
surfaces. This is disrupted in peptides (pep-20 and pep-21) with direct contacts between K6 and 
W7 side chains. C, A similar structural motif as C1aB is observed in munc18 W28K29 when 
bound to syntaxin (PDB 4JEH). D, Peptide array binding assay of the C1aB sequences with 
sequential alanine substitutions, one residue at a time. Tryptophan to alanine-substituted peptides 
had significantly less syntaxin binding than the parent peptide (*p<0.05; ANOVA/Dunnett). 




Figure 10. Docked C1aB peptide recapitulates interactions of munc18/syntaxin co-crystal. 
Closed form of syntaxin from munc18 co-crystal (PDB 4JEH) is shown in green and cyan 
(surface/sticks) corresponding to the Habc and the H3 domains, respectively. Syntaxin F34 is 
shown in magenta to emphasize specific aromatic stacking interaction in all panels. A, Partial view 
of munc18/syntaxin co-crystal. Orange sticks show same munc18 peptide as in Fig. 9C, other 
munc18 residues making favorable interactions are shown in yellow sticks. Red sphere highlights 
fully coordinated crystal water. B, Unbiased docking model of C1aB/syntaxin. C, Highlighted 
intermolecular interactions of munc18/syntaxin that are recapitulated in D, detailed view of 
interactions between docked pose of C1aB and syntaxin. Specifically, munc18 W28 aromatic 
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stacking is mimicked by C1aB W7; hydrophobic interactions between munc18 I57 and T56 and 
syntaxin I115 are mirrored by C1aB W9 (blue shade); hydrogen bond between munc18 T48 and 
syntaxin D231 is reproduced by H1 in C1aB (red shade). Syntaxin is identical in all the structures 
with the exception of Q119 and T122 sidechains in C1aB/syntaxin, which, in the absence of the 
crystal water, rotate slightly to satisfy its hydrogen bonds and methyl group interactions. 
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Figure 11. Virtual screening discovered six compounds (cpd1-6) that potentially recapitulates munc18/C1aB 
interactions with syntaxin. 
A, Interactions between cpd1-6 and syntaxin. For cpd5 specifically, benzothiazole ring forms 
stacking interaction with F34, with urea moeity fully recapitulating hydrogen bonds formed by 
crystal water in munc18 (red sphere). Water molecule is shown as a guide to highlight the overlap 




Figure 12. Cpd5 suppresses death-inducing Kv2.1 current and is a neuroprotective agent. 
A, Representative figures of the neuronal culture treated with TBOA, with and without cpd5 pre- 
and co-incubation. Phase-bright cells represent neurons. In subsequent panels, neurons transfected 
with eGFP plasmid after identical treatment as described. Scale bar denotes 100 μm in all panels. 
B, Incubation of cortical culture neurons with 10 μM cpd5 was found to be highly neuroprotective 
against 75 μM TBOA-induced excitoxicity. This protective effect was comparable with its peptide 
counterpart, TAT-C1aB (1 μM). (Vehicle vs cpd5 vs TAT-C1aB relative toxicity mean ± SEM: 
3.70 ± 0.33 vs 1.84 ± 0.42 vs 1.89 ± 0.15; *p<0.05; Kruskal-Wallis non-parametric ANOVA; n = 
3-8). Relative toxicity is defined as LDHTBOA+cpd5/LDHcpd5 C, Representative current traces (top) 
and plots of the evoked delayed rectifier currents at +30 mV. The 50 μM TBOA-evoked increase 
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in delayed rectifier current was significantly suppressed by the presence of 10 μM cpd5 (DMSO 
vs TBOA vs cpd5+TBOA: 85.92 ± 13.53 vs 139.28 ± 9.05 vs 100.12 ± 9.61 pA/pF; One-way 
ANOVA/Dunnett, *p<0.05). Scale bar indicates 1000 pA and 20 ms; n = 10-12. D, Cpd5 (10 μM) 
did not inhibit NMDA-induced Ca2+ responses in cultured cortical neurons (% Control ± SEM, F-
peak treated 101.26 ± 1.47, AUC treated 104.67 ± 1.98, *p>0.05; t-test). Responses shown are the 
average of 40 Fura-2 loaded cells in 2 separate coverslips. Four coverslips were utilized for our 




Figure 13. Cpd5 competitively binds syntaxin against C1aB-containing Kv2.1 peptides. 
Peptide array binding assay of the proximal Kv2.1 C-terminus (C1a) region using 15 a. a. segments 
spanning residues Kv2.1 451–540, in overlapping 1 a. a. steps. Bar graph shows the summary (n 
= 4) of syntaxin binding intensity in the presence of 100 μM cpd5 or 0.1 % DMSO as vehicle 
control. The C1a binding sequence is highlighted in red. *p<0.05, non-parametric Mann-Whitney 
for each peptide. Inset, Average concentration-dependent effect of cpd5 on syntaxin binding to 
the peptides 22-28 (containing the full C1aB domain; n=4 for each peptide) of the peptide array. 
Percent inhibition of syntaxin binding compared to 0.1 % DMSO is plotted for various 
concentrations of cpd5. The fitted sigmoid curve to the pooled, averaged data is shown in red.  The 
data were fitted in GraphPad Prism with a log (inhibitor) vs normalized pooled response with a 




Figure 14. Cpd5 (10 μM) does not affect evoked AMPAR EPSCs in layer 2/3 corticocallosal neurons in the 
mouse auditory cortex. 
A, Left: Schematic of stereotaxic injections for labeling of corticocollicular and corticocallosal 
neurons with different flourospheres to identify select neurons in the auditory cortex for acute slice 
electrophysiology. Right: Schematic illustrating slice electrophysiology experiment involving 
electrical stimulation of auditory cortex layer 2/3 while recording from adjacent labeled 
corticocallosal neurons. B, Representative traces of a layer 2/3 corticocallosal neuron AMPAR 
EPSCs evoked by electrical stimulation of adjacent layer 2/3 sites while incubated in control 
(black) and in 10 µM cpd5 (red). C, Time course of the average amplitude of AMPAR EPSCs 
before and after cpd5 treatment. D, Average effect of cpd5 (red) on layer 2/3 corticocallosal neuron 
AMPAR EPSCs amplitudes, normalized to control (control vs. cpd5: 97.6 ± 0.9%, p = 0.153, 
paired t-test, n = 4 cells from 4 mice).   
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Figure 15. Small molecules discovered in virtual screening. 
A, Full name and abbreviations of the six compounds selected for study after ZINCPharmer virtual 
screening and all-atom optimization based on the discussed pharmacophores. B, Chemical 
structure of the compounds selected for testing. Images adapted from Molport. C, LDH toxicity 
assay screening of four small molecules evaluated for innate toxicity to primary rat cortical neuron 
cultures. Relative toxicity is defined as LDHTreatment/LDHVeh D, LDH toxicity assay screening of 
the lead compound cpd5 in primary cortical neuron cultures found no innate toxicity of up to 30 
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μM for 24 hr. E, Incubation of cortical culture neurons with 10 μM cpd3, cpd4, or cpd6 provided 
no neuroprotection against 75 μM TBOA-induced excitoxicity (Vehicle vs cpd3 vs cpd4 vs cpd6 
relative toxicity mean ± SEM: 2.99 ± 0.32 vs 2.75 ± 0.72 vs 3.48 ± 1.1 vs 3.12 ± 0.65; Kruskal-
Wallis non-parametric ANOVA; n=3-9). Relative toxicity here is defined as LDHTBOA+cpd/LDHcpd. 
F, Cpd5 does not decluster Kv2.1. Cortical culture neurons were transfected with Kv2.1-eGFP and 
incubated in 10 µM cpd5 for 24 hr. No declustering effects were observed. Mean clusters per µm2 




Figure 16. Cpd5 disrupts munc18/syntaxin binding at high concentrations. 
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A, A graphical summary of co-immunoprecipitation experiments using HEK293 cells transfected 
with munc18 and syntaxin in the presence of 10, 30, or 100 μM cpd5. Cells incubated in either 30 
or 100 μM cpd5 showed a significant displacement of munc18 from syntaxin. Cpd5 at the 
concentration that we have observed neuroprotection (10 μM) did not displace munc18 from 
syntaxin. One representative blot from each concentration is presented above. (From 10 to 100 
μM: 1.032 ± 0.034, 0.4459 ± 0.09367, 0.4339 ± 0.135, cpd5/DMSO mean ± SEM; *p<0.05, 
Tukey’s multiple comparisons, n=3 each). B, Evaluation of antibodies used in the co-IP 
experiments. We evaluated antibody specificity varying the transfection composition and probed 
with individual antibodies. Top: We confirmed the 68 kDa band to be munc18 and the 33 kDa 
band to be syntaxin 1A by observing that they do not appear in samples without prior transfection 
with appropriate plasmids in HEK cells. The munc18 antibody does not detect the syntaxin band. 
In the first blot, munc18 was probed first, followed by syntaxin. Bottom: In a separate run of the 
same sample, we confirmed the specificity of the syntaxin antibody by probing with the syntaxin 
antibody only, observing relatively lack of signal at the MW for munc18. The co-transfection of 
munc18 with syntaxin appears to induce a formation of a higher molecular weight syntaxin species. 




Figure 17. Cpd5 does not affect intrinsic electrical properties of layer 5B corticocollicular neurons in the mouse 
auditory cortex. 
A, Schematic illustrating slice electrophysiology experiment evaluating the intrinsic properties of 
L5B corticocollicular neurons after retrograde labeling as shown in Fig. 14A Left. B-D, An 
evaluation of subthreshold intrinsic properties found a lack of significant effect of cpd5 incubation 
on (B) resting membrane potential, (C) input resistance, or (D) sag ratio (V2/V1). E-G, An 
evaluation of evoked properties also found no significant effect of cpd5 incubation on (E) action 
potential threshold, (F) width, or (G) firing rate. Available representative traces are provided for 
each experiment. Each neuron is evaluated before and after 10 min incubation in 10 μM cpd5 
(Paired t-test; for firing rates, 2-way ANOVA; n=4 cells from 4 mice). 
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3.4 Discussion 
The interaction between the intrinsically disordered proximal C-terminus of the delayed 
rectifier Kv2.1 (C1a) and the SNARE protein syntaxin was first characterized nearly 15 years ago 
by Gaisano, Lotan, and co-workers (Leung et al., 2003; Singer-Lahat et al., 2007; Singer-Lahat et 
al., 2008). Recent work in our laboratory narrowed down the involved Kv2.1 C1a region to 50 
amino acids (McCord et al., 2014), and then to the 9 amino acids sequence termed C1aB (Yeh et 
al., 2017). Preventing the interaction between Kv2.1 and syntaxin by either overexpressing C1a or 
using the cell-permeant TAT-C1aB peptide are effective neuroprotective strategies in both in vitro 
and in vivo models of acute neuronal injury (McCord et al., 2014; Yeh et al., 2017). Here, we 
report the discovery of a first-in-class neuroprotective small molecule inhibitor (cpd5) of the 
protein-protein interaction between syntaxin and Kv2.1. Using molecular dynamics simulations of 
intrinsically disordered peptides containing the Kv2.1 syntaxin-binding sequence C1aB 
(HLSPNKW7KW) and docking, we predicted the aromatic residue W7 to be a critical binding 
motif to syntaxin (Fig. 9). This prediction was validated by alanine scanning of individual C1aB 
residues and competitive binding assays of C1a-derived peptides that demonstrated inhibition of 
only those peptides containing W7 (Fig. 9D, 13). Furthermore, we predicted C1aB to bind on the 
rim of the munc18’s interactions with syntaxin (Fig. 10A, 10B), suggesting that munc18 should 
form a much tighter complex with the closed conformation of syntaxin than C1a.    
Most importantly, we demonstrate the Kv2.1/syntaxin binding as a highly promising target 
for eliciting neuroprotection that does not appear to have any detrimental effects in the neuronal 
cell types examined. Notably, cpd5 at 10 μM is neuroprotective, effectively displacing Kv2.1 
C1aB peptides from syntaxin without affecting the binding between munc18 and syntaxin, which 
we show to only occur at much higher concentrations (Fig. 16A). Indeed, the mechanism of action 
 79 
predicted for cpd5 shows that besides the aromatic interaction with syntaxin F34, cpd5 competes 
for direct intermolecular hydrogen bonds and non-polar contacts formed by C1aB with syntaxin, 
whereas only the water-mediated interactions are significantly disrupted in the munc18-syntaxin 
binding (Fig. 10C, 10D, 11A). Further, the loss of the entire syntaxin N-terminal Habc globular 
domain, which includes the F34 residue, does not impede vesicle fusion induced by munc18 (Shen 
et al., 2010), indicating that exogenous competition at the F34 binding site is not immediately 
deleterious to SNARE functions. 
We have never observed the suppression of basal Kv2.1 current when targeting syntaxin. 
Cpd5 neither suppressed Kv2.1 current below its control levels nor increased cortical neuron 
excitability, which is consistent with our previous observations with C1a and TAT-C1aB (McCord 
et al., 2014; Yeh et al., 2017). This suggests distinct trafficking mechanisms between basal and 
death-promoting Kv2.1 channel populations. The death-promoting Kv2.1 population has been 
shown to be inserted de novo after lethal insults (Pal et al., 2006), and requires the existence of 
non-conducting Kv2.1 surface clusters that act as general protein trafficking hubs when in contact 
with the endoplasmic reticulum (Fox et al., 2015; Justice et al., 2017). On the other hand, the basal 
Kv2.1 population does not appear to require the interaction with syntaxin, as botulinum 
neurotoxin-mediated loss of syntaxin and SNAP-25 function only suppresses the expression of the 
pro-death Kv2.1 currents (Pal et al., 2006). These findings strongly support the idea that basal 
Kv2.1 maintenance is largely syntaxin-independent and is unaffected by our neuroprotective 
strategy of targeting a putatively dedicated cell death pathway. The fact that Kv2.1 can be 
selectively transported for distinct functions was recently reinforced by a study showing that 
phosphoregulation of a Kv2.1 target sequence motif (a. a. 720-745) can lead to Golgi-independent 
trafficking of the channel to the axon initial segment (Jensen et al., 2017). In the same vein, we 
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propose that injury-dependent phosphorylation of Kv2.1 Y124 and S800 (Redman et al., 2009) 
drives pro-death trafficking of Kv2.1 to the membrane via the syntaxin-dependent process 
described here. 
Kv2.1 serves several non-conducting functions through its large cytosolic domains. Most 
prominently, Kv2.1 directly interacts with members of the SNARE complex, SNAP-25 and 
VAMP2 (MacDonald et al., 2002; Lvov et al., 2008), in addition to syntaxin, to facilitate 
exocytosis and vesicle fusion in several cell types. In neuroendocrine cells, the Kv2.1-syntaxin 
interaction has been shown to facilitate exocytosis of dense core vesicles independent of Kv2.1’s 
ion channel functions (Singer-Lahat et al., 2008). In pancreatic β cells, the Kv2.1-syntaxin 
interaction modulates the release of insulin. Namely, clustered Kv2.1 domains in secretory β cells 
are known to facilitate insulin granule release through the selective binding of Kv2.1 C1a (a.a. 
411-522) and C1b (a.a. 523-621) to syntaxin 1A and syntaxin 3, respectively, eliciting the secretion 
of distinct granules populations (Zhu et al., 2013; Greitzer-Antes et al., 2018). Interestingly, 
syntaxin 3 has a significantly reduced affinity to C1a. The aligned amino acids sequence of 
syntaxin 1A and syntaxin 3 revealed a number of distinctions in the immediate residues near the 
central phenylalanine identified in this study (aligning syntaxin 1A’s F34 to syntaxin 3’s F36; 
UniProt alignment: Q16623 STX1A_HUMAN, Q13277 STX3_HUMAN). Specifically, in 
syntaxin 1A, the amino acids glutamic acid-glutamine-valine (EQV) follows the phenylalanine, 
while in syntaxin 3, it is serine-glutamic acid-isoleucine (SEI). More studies will be necessary to 
evaluate how these amino acids sequence distinctions lead to differences in binding preference. 
Recently, Kv2.1 has been found to associate with the endoplasmic reticulum proteins VAPA and 
VAPB to form distinct channel clusters at contact points between the plasma membrane and the 
endoplasmic reticulum (Johnson et al., 2018; Kirmiz et al., 2018). These clusters have been shown 
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to be necessary for the trafficking of the death-promoting population of Kv2.1 (Justice et al., 2017), 
suggesting that the interaction between Kv2.1 and the VAP proteins may be involved in cell death 
processes.  
With the discovery of cpd5 as a first-in-class neuroprotective agent, we demonstrate a 
translational workflow that utilizes structural modeling to guide the resolution of protein-protein 
interactions involving poorly characterized disordered domains, leading to both mechanistic 
insights and the identification of an effective new drug. To this end, the approach of temporarily 
disrupting a protein-protein interaction for neuroprotection is a recently proven successful 
translational venture, as seen with the TAT-NR2B9c peptide, a currently phase III treatment for 
acute ischemic stroke that ameliorates excitotoxicity by displacing NMDA receptor function from 
nitric oxide production (Ballarin & Tymianski, 2018). While we have shown that disrupting the 
Kv2.1/syntaxin interaction is also efficacious in a mouse model of acute ischemic stroke (Yeh et 
al., 2017), there is an increasing indication of Kv2.1 involvement in even broader contexts of 
neurodegenerative conditions, including chronic and progressive neurologic disorders (McCord & 
Aizenman, 2014; Shah & Aizenman, 2014; Chao et al., 2018; Yu et al., 2018). This reflects the 
fact that oxidative stress is a major component of most neurodegenerative conditions (Liu et al., 
2017) and is known to drive the Kv2.1-mediated cell death pathway (Aizenman et al., 2000). As 
such, cpd5 is not only a first in class neuroprotective molecule, it represents an important step in 
realizing the therapeutic potentials of targeting Kv2.1 in neurodegenerative disorders. 
  
 82 
3.5 Materials & Methods 
Statement of access. Experimental data, models, and analysis presented here are available 
upon request to the corresponding authors. 
Molecular dynamics modeling. All initial structures of the 9-mer Kv2.1-derived peptides 
were built using PyMOL 1.7 (Schrodinger, 2010). The C-terminus of the peptides were N-
methylated. The molecular dynamics (MD) simulations were run with pmemd.cuda (Götz et al., 
2012) from AMBER14 (Case et al., 2014) using AMBER ff12SB force field. We used the tLEaP 
module from AMBER14 to center each individual peptide on an octahedral TIP3P water 
box(Jorgensen et al., 1983) with a 15 Å distance from the protein surface to the box edges and 
closeness parameter of 0.75 Å. The system was neutralized by adding the appropriate number of 
Cl- ions. In the first energy minimization step, the solute was fixed and we performed two rounds 
of solvent relaxation through 2,500 cycles of steepest descent followed by 2,500 cycles of 
conjugate gradient minimization. After minimization, we performed a 50 ps constant volume 
simulation to raise the temperature of the system to 300 K. Temperature scaling was achieved 
using the Langevin thermostat (Loncharich et al., 1992) with a collision frequency of 1.0 ps-1. We 
then ran a 50 ps constant pressure simulation at 300 K using the same temperature scaling scheme. 
Pressure was maintained at 1 bar (0.987 atm) using periodic boundary conditions with isotropic 
position scaling and the Berendsen thermostat (Berendsen et al., 1984) with a pressure relaxation 
time of 2.0 ps. Both the temperature and pressure equilibration MDs used an integration timestep 
of 2 fs, and coordinates were written to file every 250 steps. Solute heavy atoms were fixed using 
a harmonic restraint weight of 500.0 kcal/mol∙A2, and bonds involving hydrogens were constrained 
at constant length using the SHAKE algorithm (Ryckaert et al., 1977). The non-bonded interaction 
cutoff was 8 Å. Initial velocities were generated randomly from a Maxwell distribution at 300 K. 
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All production runs were with only the backbone of this C-terminal residue constrained for 200 
ns. All following up calculations used the trajectories after 50 ns.   
Virtual Screening using ZINCPharmer. The structure of the syntaxin is obtained from 
PDB 4JEH. Several pharmacophores models were built based on the munc18/syntaxin interactions 
using ZINCPharmer (Koes & Camacho, 2012). An aromatic sphere was placed close to F34 as pi-
pi stacking of the aromatic rings. A hydrogen acceptor sphere was placed to match Q119. A 
hydrogen donor sphere was placed to match Q119 and D231. A hydrophobic sphere was placed in 
the F34-V37-L123 hydrophobic pocket. One aromatic and one hydrophobic sphere were placed 
between the R41 and K126 to match the pi-pi stacking and backbone interactions respectively. The 
number of primary hints of compounds was 39,892. These structures were then submitted to 
SMINA (Koes et al., 2013) for structural minimization, and the conformations with RMSD larger 
than 1.5 Å were removed. A final list of six compounds were then utilized for further experimental 
testing.  Compounds were purchased from Molport. 
Cortical cultures, LDH assay, and calcium measurements. All animal protocols described 
here and below were approved by the Institutional Animal Care and Use Committee of the 
University of Pittsburgh School of Medicine. Cortical neurons were prepared from embryonic day 
16-17 rats of either sex as described previously (McCord et al., 2014). Pregnant donor rats (Charles 
River Laboratories) were killed by gradual CO2 inhalation, an American Veterinary Medical 
Association approved protocol (Leary et al., 2013). Cortices were dissociated with trypsin, and 
plated at 670,000 cells per well on poly-L-ornithine glass coverslips in six-well plates as described 
previously (Hartnett et al., 1997). Non-neuronal cell proliferation was inhibited with 1–2 µM 
cytosine arabinoside at 15 days in vitro (DIV). All cortical culture experiments shown here were 
performed on 18-25 DIV cultures. 
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DL-threo-β-benzyloxaspartate (TBOA; Tocris Bioscience) excitotoxicity assays were 
performed on cortical culture coverslips transferred into 24-well plates containing 10 mM HEPES, 
0.01 % bovine serum albumin (BSA)-supplemented MEM without phenol red (MHB). On each 
individual plate, coverslips were treated with vehicle control or 75 µM TBOA in wells that had 
been preincubated for 1 hr with either 10 µM of the indicated treatment or vehicle at 37°C,5% CO2 
for 24 hr. Following this exposure, external medium was collected for LDH colorimetric 
measurements using a toxicity kit (Sigma-Aldrich), as previously described (Aras et al., 2008). 
Each experiment contained three replicates of four conditions (with/without TBOA, with/without 
treatment). Relative toxicity was quantified as the LDH ratio of TBOA-treated over vehicle control 
values within each experiment. For visualization of the cell cultures, coverslips were imaged at 
20x using a QCapture camera system. 
Intracellular Ca2+ measurements were performed essentially as previously described 
(Aizenman et al., 1990) on the same cortical culture preparations as above, but with 20 DIV cells 
plated on MatTek glass-bottom 35 mm culture dishes. At this developmental stage, neurons 
robustly express both GluN2A and GluN2B subunits of the NMDA receptor (Sinor et al., 2000). 
Neurons were incubated with the fluorescent Ca2+ indicator Fura-2 AM ester (5 µM; Invitrogen) 
with 0.02% Pluronic F-127 (Invitrogen) for 1 h at 37°C. Culture dishes were then mounted on an 
inverted microscope stage (Olympus) and continuously perfused with a 10 mM HEPES-buffered 
normal salt solution. Perfusion rate (5 ml/min) was controlled with a gravity flow and a rapid-
switching local perfusion system (Warner Instruments). Firmly attached refractile cells were 
identified as regions of interest (ROIs; 4 coverslips, ~40 cells/coverslip). A ratio of fluorescence 
emission (F) at 510 nm in response to excitations at 340 and 380nm was acquired at 1Hz (Lambda 
DG-4 and 10-B SmartShutter, Sutter Instruments) via camera (ORCA-ER, Hamamatsu) and saved 
 85 
to a computer using HCImage (Hamamatsu). Baseline Ca2+ signals were recorded for 2 min before 
the first application of NMDA (30 µM plus 10 µM glycine) with or without 10 µM cpd5 (Cat# 
MolPort-009-741-732, Molport). The second exposure to NMDA is given 4 minutes later. Peak 
increases in intracellular calcium concentration were measured by calculating F/Fo (F, peak 
fluorescence; Fo, average signal across 2 min baseline period). The area under the response for the 
first 15 min of NMDA application was also calculated. 
Confocal imaging. For live imaging, neurons were transfected using Lipofectamine-2000 
with plasmids expressing eGFP. Twenty-four hours later neurons were treated with TBOA (75 
µM) alone or in combination with 10 µM cpd5.  Cells were visualized 24 hours later on a Nikon 
A1+ confocal microscope. An additional group of cells were transfected with eGFP-tagged Kv2.1 
and 24 hours later exposed to vehicle or 10 µM cpd5 overnight.  For imaging, five–ten optical 
sections (0.5 μm) were acquired to generate a maximum intensity projection image that was 
analyzed for channel cluster counts and surface area using Nikon Instruments Elements Advanced 
Research software as described previously (Justice et al., 2017).  This experiment was repeated 3 
separate times and images were obtained from 21 independent fields per condition.  
Peptide spot array and binding assay. Peptide array protein-binding affinity assays were 
performed as previously described (Brittain et al., 2011b; Wilson et al., 2011; Brittain et al., 2012a; 
Wilson et al., 2012; Moutal et al., 2017; Yeh et al., 2017; Francois-Moutal et al., 2018). Peptide 
spot arrays (15 mers) spanning the proximal C-terminus residues 451–540 of rat Kv2.1 were 
constructed using the Spots-synthesis method. Standard 9-fluorenylmethoxy carbonyl (Fmoc) 
chemistry was used to synthesize the peptides and spot them onto nitrocellulose membranes 
prederivatized with a polyethylene glycerol spacer (Intavis). Fmoc protected and activated amino 
acids were spotted in quadruplicates on 20–30 arrays on 75 by 25 mm membranes using an Intavis 
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MultiPep robot. The nitrocellulose membrane containing the immobilized peptides were 
rehydrated in Tris-buffered 0.1% Tween 20 (TBST) for 10 min, and then blocked for 1 h at room 
temperature (RT) with gentle shaking in TBST containing 5% (w/v) nonfat dry milk and then 
incubated with enriched STX1A protein containing the indicated concentrations of cpd5 for 1 h at 
RT with gentle shaking. Next, the membrane was incubated in primary antibody for syntaxin 1A 
(Millipore, catalog #AB5820-50UL, RRID:AB_2216165) for 2h at RT with gentle shaking, 
followed by washing with TBST. Finally, the membrane was incubated in secondary antibody 
(goat anti-rabbit DyLight 800, catalog #355571, Thermo Fisher Scientific) for 45 min, washed for 
3 times 5 min in TBST, and visualized by infrared fluorescence (Li-Cor).  Similar procedures were 
followed for the alanine scan study with 9-mers.  
Cortical culture electrophysiology. Whole-cell patch-clamp experiments were performed 
on rat cortical culture neurons prepared as described in the LDH toxicity experiments. The TBOA 
treatment was reduced in severity in this experiment to limit extensive cell injury that would 
prevent adequate patch clamp recordings. Prior to recording, coverslips were treated with 50 μM 
TBOA in MHB for 2 hr. The treatment was terminated with 3x MHB washes and by transferring 
the coverslip to a separate well containing MHB to rest for 2 hr prior to electrophysiology 
recordings and to allow for the expression of enhanced currents. For cpd5-treated groups, cells 
were pre-incubated for 1 hr in 10 µM cpd5 prior to the addition of TBOA. Cpd5 was also present 
during the TBOA and the post-TBOA incubation phases. 
Recordings were carried out using 1.5 mm diameter borosilicate glass electrodes (Sutter 
Instruments) made from a horizontal pipette puller at approximately 6 MΩ. The internal solution 
contained (in mM): 100 K-gluconate, 10 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, 11 EGTA, 2.2 ATP, 
0.33 GTP. The internal solution was further adjusted to pH 7.2 and to 280 mOsm with the addition 
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of sucrose. The pH adjusted (7.2) external solution was composed of the following (in mM): 115 
NaCl, 2.5 KCl, 2.0 MgCl2, 10 HEPES, 10 D-glucose, and 0.25 µM TTX. Once whole-cell 
configuration has been achieved, delayed rectifier currents were evoked with 185 ms voltage steps 
from a holding potential of -80 mV to +80 mV in +10 mV increments. Recordings were filtered at 
2 kHz and digitized at 10kHz (Digidata 1440A, Molecular Devices). Series resistance was 
compensated at 80% for all recordings. Analysis of current density was carried out at the +30 mV 
voltage step, taking the mean value of the steady-state current between 150 and 175 ms over the 
whole-cell capacitance (~10 pF). Space clamp is not generally an issue, as Kv2.1 is primarily 
expressed in the soma and very proximal neurites.  Moreover, we quantified our results at +30 mV, 
where currents are normally not much larger than 2 nA after TBOA.  Normality of the data was 
confirmed via Shapiro-Wilk test. 
Stereotaxic injections for electrophysiology. Male or female ICR mice P21-30 (Jackson 
Laboratory) were anesthetized with 3% isoflurane (1.5% maintenance) and placed on the 
stereotaxic frame (Kopf). Core body temperature was maintained at ~37 °C with a heating pad and 
eyes were protected with ophthalmic ointment. Lidocaine (1 %) was injected under the scalp and 
an incision was made into the skin at the midline to expose the skull. To retrogradely label 
corticocallosal neurons and corticocollicular neurons in the auditory cortex, the contralateral 
auditory cortex (PLV -4, +4, +1 mm bregma) and the ipsilateral inferior colliculus (PLV -1, +1, -
0.75 mm lambda) respectively were injected with retrograde tracer beads (Lumafluor) through a 
small craniotomy. A volume of ~0.12 µl fluorospheres was pressure injected (25 psi, 10 ms 
duration) from capillary pipettes (Drummond Scientific) with a Picospritzer (Parker–Hannifin). 
After injection, the pipette was held in the brain for 2 min before slowly withdrawing. The scalp 
of the mouse was closed with cyanoacrylate adhesive. Mice were injected with the non-steroidal 
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anti-inflammatory drug carprofen at 5 mg/kg (Henry Schein Animal Health) for 24 hours prior to 
and 48 hours after surgery. Mice were monitored for signs of postoperative stress and pain. 
Slice electrophysiology. Slice electrophysiology experiments were performed in mice at 
least 2 days after fluorospheres injections. Following anesthesia with isoflurane, mice were 
immediately decapitated. Brains were rapidly removed and coronal slices (300 μm) containing the 
auditory cortex were prepared in a cutting solution at 1 oC using a Vibratome (VT1200 S; Leica). 
For evoked EPSC recordings, the cutting solution, pH 7.4, ∼300 mOsm, contained the following 
(in mM): 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 0.5 CaCl2, 7 MgCl2, 7 Glucose, 205 sucrose, 1.3 
ascorbic acid, and 3 sodium pyruvate (bubbled with 95% O2/5% CO2). For evaluation of 
corticocollicular neuron electrical properties, the cutting solution, pH ~7.4, contained the 
following (in mM): 135 NMDG, 1 KCl, 1.2 KH2PO4, 1.5 MgCl2, 1.5 CaCl2, 20 NaHCO3, 10 D-
Glucose. The slices were then transferred and incubated at 34°C for 30 min (bubbled with 95% 
O2/5% CO2) prior to recording. The incubating and recording solution contained the following (in 
mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1 MgCl2, 10 D-Glucose, 1.3 
ascorbic acid, and 3 sodium pyruvate (bubbled with 95% O2/5% CO2). Slices were stored at room 
temperature until the time of recording. The flow rate of the ACSF was ~1.5 ml/min, and its 
temperature was maintained at 34°C using an in-line heating system (Warner). Both slice 
electrophysiology experiments were carried out using MultiClamp-700B amplifier equipped with 
Digidata-1440A A/D converter and Clampex (Molecular Devices). Data were sampled at 10 kHz 
and Bessel filtered at 4 kHz. Pipette capacitance was compensated and series resistance for 
recordings was lower than 15 MΩ and measured throughout the experiments. Recordings were 
excluded from further analysis if the series resistance changed by more than 15% compared to the 
baseline period. 
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To evoke AMPAR EPSCs, auditory cortex layer 2/3 neurons were stimulated locally with 
an Isoflex stimulator (AMPI), through a glass theta electrode containing ACSF, by a single 0.15 
ms duration electrical pulse every 30 sec. AMPAR EPSCs were recorded in voltage clamp mode 
at -70 mV (peak values were averaged over a 0.3 ms time window).   
All data for intrinsic properties were acquired and analyzed within the Ephus software 
package. Series resistance was determined in voltage-clamp mode (command potential set at −70 
mV) by giving a −5 mV voltage step. Series resistance was determined by dividing the −5 mV 
voltage step by the peak current value generated immediately after the step in the command 
potential Rinput was calculated in voltage-clamp mode (command potential set to −70 mV) by 
giving a −5 mV step, which resulted in transient current responses. The difference between 
baseline and steady-state hyperpolarized current (ΔI) was used to calculate Rinput using the 
following formula: Rinput = −5 mV/ΔI − Rseries. The average resting membrane potential (Vm) was 
calculated by holding the neuron in voltage-follower mode (current clamp, at I = 0) ~2 minutes 
after breaking in and averaging the membrane potential over the next 30 sec. Subthreshold and 
suprathreshold membrane responses in current clamp were elicited by injecting −200 to +400 pA 
in 50 pA increments (baseline Vm was maintained at −70 mV, by injecting the required current, if 
necessary). Sag was measured during the −200 pA current injection, using the formula, SAG = 
(Vmin − Vsteady-state)/Vsteady-state. The first resulting action potential (AP) at rheobase was analyzed for 
AP width. AP width was calculated as the full-width at the half-maximum amplitude of the AP.  
Both slice electrophysiology experiments utilized borosilicate pipettes (World Precision 
Instruments) pulled into patch electrodes with 2.5–6 MΩ resistance (Sutter Instruments) and filled 
with a potassium-based intracellular solution, which was composed of the following (in mM): 128 
K-gluconate, 10 HEPES, 4 MgCl2, 4 Na2ATP, 0.3 Tris-GTP, 10 Tris phosphocreatine, 1 EGTA, 
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and 3 sodium ascorbate (pH = 7.25, 295 mOsm). Normality of the data collected was confirmed 
via Shapiro-Wilk test. 
Western Blot. Co-immunoprecipitation of munc18 and syntaxin was carried out using PEI 
transfection of HEK293 cells (American Type Culture Collection) plated and maintained in 
DMEM medium with 10% FBS and penicillin/streptomycin. Twenty-four hr prior to transfection, 
HEK293 cells were plated onto 150 mm petri dishes from confluent T75 flasks at the ratio of 2/3 
flask per plate. 24 hr after plating, PEI transfection was carried out by mixing 25% munc18 
(OriGene RC204873), 25% syntaxin 1A (gift from Raymond A Frizzell, Children’s Hospital of 
Pittsburgh), and 50% pcDNA3 (Invitrogen) plasmids (28 µg total plasmids with 500 µl medium 
without penicillin/streptomycin, and 110 µl PEI at 1 mg/ml). The PEI was lastly added to the 
mixture drop-wise to avoid clumping of the DNA precipitates. This transfection reagent was 
allowed to incubate in room temperature for at least 5 min. The HEK293 medium was replaced 
with medium without penicillin/streptomycin prior to the addition of the transfection mixture. At 
24 hr after transfection, the transfection medium was replaced with regular medium containing 
either cpd5 or DMSO. The cells were lysed and protein was harvested 24 hr after cpd5/DMSO 
treatment using 200 µl NP40 buffer (Invitrogen) containing phenylmethylsulfonyl fluoride 
(PMSF, Sigma-Aldrich) and protease inhibitor cocktail (1/4 tablet, cOmplete Mini, EDTA-free, 
Sigma-Aldrich). The resulting HEK293 sample was immunoprecipitated using mouse anti-
syntaxin 1A antibody (abcam). The western blot was probed using the Biogen system with the 
same syntaxin 1A antibody and mouse anti-Flag (Sigma-Aldrich) used for the detection of 
munc18. Quantification of protein pulldown was normalized to the syntaxin signal before 
comparisons. SDS-PAGE in this study were run in 10% acrylamide. Small variations in band 
separation were caused by the semi-wet transfer method. 
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4.0 Injury-dependent expression of HCV protein NS5A ameliorates striatal infarct in vivo 
4.1 Section Summary 
The hepatitis C virus (HCV) protein NS5A prevents the enhancement of death-permitting 
Kv2.1 potassium current, increasing cell viability in hepatocytes and, ectopically, in neurons. 
Taking advantage of the injury-dependent release of cytosolic zinc in the Kv2.1-dependent 
neuronal cell death pathway, we previously utilized the metal regulatory transcription factor 1 
(MTF-1)/metal regulatory element (MRE) system to drive the expression of NS5A and provide 
neuroprotection in vitro. Here, we demonstrate that this neuroprotective strategy is also feasible in 
the mouse brain. We generated serotype 9 adeno-associated virus containing the MRE-driven 
NS5A construct (AAV9-4xMRE-NS5A.eGFP) and injected it unilaterally into the mouse striatum. 
The injection of this virus did not elicit any observable abnormal behaviors or liver toxicity after 
more than 1 month post-injection. When mice were challenged with a transient focal ischemic 
stroke, strong neuronal NS5A expression was observed within 3 hr in several brain regions 
ipsilateral to the lesion. Importantly, animals treated with the AAV9-4xMRE-NS5A.GFP virus 
exhibited reduced striatal infarction when compared to a control, GFP-expressin vector. These 
results provide in vivo confirmation that the MTF-1/MRE expression system can be exploited to 
elicit injury-dependent expression of specific proteins and that the HCV protein NS5A can be 





Many essential therapeutic drugs on the market today began their development as naturally 
occurring compounds. An evolutionary arms race exists in all biological faunas, driving the 
emergence of highly refined and selective protein-protein interactions. The survival and 
propagation of the hepatitis C virus (HCV) in host liver hepatocytes is an example of such a 
mutually competitive relationship between two organisms. Extensive research has aimed to 
understand the molecular mechanisms underlying HCV persistence and its ability to proliferate, 
inhibit antiviral mechanisms, and maintain host cell viability. Many of these viral functions involve 
the direct interactions with the host cell. For example, the expression of several HCV proteins 
itself requires post-processing by host proteases (Tellinghuisen et al., 2007). The HCV proteins 
NS2 and NS3/4A were identified as potent inhibitors of host cytokine gene expression to avoid 
anti-viral functions (Kaukinen et al., 2006). Another highly studied HCV protein that interacts 
with host cellular functions is the non-structural protein NS5A, which is known to have a direct 
role in viral replication, virion production, and importantly, the suppression of host cell’s ability 
to commit apoptosis (He et al., 2006; Mankouri et al., 2009). 
Physiological levels of potassium concentration prohibit the formation of the apoptosome 
and other cell death program components (Bortner & Cidlowski, 2007). Thus, the depletion of 
intracellular potassium is a necessary step in the execution of cell death pathways. In hepatocytes 
and many neuronal subtypes, Kv2.1 is the main mediator of this potassium loss. Experimental 
evidence has shown that NS5A prevents the enhancement of Kv2.1 currents during cell death and 
improves host cell survivability (Mankouri et al., 2009; Norris et al., 2012). This is achieved by 
the inhibition of kinases responsible for two Kv2.1 phosphorylation events that promote the 
channel’s cell death functions. Specifically, NS5A inhibits the pro-death phosphorylation of Kv2.1 
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Y124 by Src Kinase (Norris et al., 2012) and Kv2.1 S800 by p38 MAPK kinase by inhibiting its 
upstream activator, mixed linage kinase 3 (Mankouri et al., 2009; Amako et al., 2013). In both 
neurons and hepatocytes, the expression NS5A is protective against lethal oxidative stress 
(Mankouri et al., 2009; Norris et al., 2012; Amako et al., 2013), mirroring extensive studies that 
show blocking potassium efflux directly or inhibiting upstream components of the Kv2.1-
dependent cell death pathway is cytoprotective (Yu, 2003; Shah & Aizenman, 2014). 
Oxidative stress is a significant component of cell death in many neurodegenerative 
diseases (Liu et al., 2017). Oxidized metalloproteins lose their ability to bind metals, such as zinc, 
releasing them into the cytosol (Marreiro et al., 2017). In injured neurons, this rise in cytosolic 
zinc is the predominant driver of the two aforementioned kinases that phosphorylate Kv2.1 for the 
expression of the death-permitting potassium current (McCord & Aizenman, 2014). Concurrently, 
unbound zinc can activate the metal regulatory transcription factor 1 (MTF-1), which translocates 
to the nucleus, driving the transcription of genes controlled by metal regulatory elements (MRE), 
such as that of metallothionein (Radtke et al., 1993) and ZnT-1 (Langmade et al., 2000). We 
previously demonstrated in vitro that 4xMRE can be used to ectopically drive the expression of 
NS5A during injury, inhibiting the Kv2.1-dependent cell death pathway and provide 
neuroprotection (Justice et al., 2018). Here, we evaluate the 4xMRE-NS5A construct in vivo and 
evaluate the feasibility of this neuroprotective module in the mouse brain with the use of adeno-
associated virus serotype 9 (AAV9) as the viral vector. 
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4.3 Results 
4.3.1  pAAV-4xMRE-NS5A.eGFP recapitulates the in vitro effects of 4xMRE-NS5A.eGFP 
To begin the in vivo translation of the 4xMRE-NS5A.GFP construct, we used traditional 
restriction enzyme cloning to transfer the gene into a commonly used AAV9 vector (pAAV9-CMV-
eGFP; John T Gray Addgene ID 32395). The resulting plasmid construct (pAAV9-4xMRE-
NS5A.GFP; Fig. 18A) is flanked by the AAV2 inverted terminal repeats that allow the selective 
packaging of the sequence into AAV capsids (Gray & Zolotukhin, 2012). To confirm that 4xMRE-
NS5A retained its neuroprotective properties when flanked by the viral cassettes in this vector, we 
evaluated it in an in vitro model of neuronal cell death as we have done previously with the original 
plasmid (Justice et al., 2018). Rat cortical culture neurons 28-34 days in vitro (DIV) were co-
transfected with luciferase and either pAAV9-4xMRE-NS5A.GFP or pcDNA3. The neurons were 
then challenged 24 hr after transfection with 60 µM TBOA, a selective glutamate reuptake 
inhibitor that we have previously shown to induce the death-permitting enhanced Kv2.1-mediated 
currents and neurotoxicity. Compared to those transfected with a vector plasmid, the neurons 
transfected with pAAV9-4xMRE-NS5A.eGFP exhibited significantly increased luciferase 
expression, a sign of cellular viability after injury (Aras et al., 2001) (Fig. 18B). This result 
successfully recapitulates previous findings with the 4xMRE-NS5A.eGFP plasmid, without the 
pre-AAV inverted terminal repeats (Justice et al., 2018). 
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4.3.2  Striatal injection of AAV9-4xMRE-NS5A.eGFP does not alter behavior,  liver 
Brain ischemia has been shown to both increase the release of cytosolic free zinc in 
degenerating neurons (Koh et al., 1996) and increase the expression of proteins regulated by MRE, 
such as metallothionein 1, 2 (Ebadi et al., 1995), and ZnT-1 (Tsuda et al., 1997). For these reasons, 
we used the mouse middle cerebral artery occlusion (MCAO) model of transient ischemic stroke 
to evaluate the in vivo neuroprotective efficacy of virally-mediated expression of 4xMRE-
NS5A.GFP. Because transient ischemic stroke cause infarct predominately covering the striatal 
regions (Yeh et al., 2017), we injected AAV9-4xMRE-NS5A.eGFP (~5.30x108 GC) into the 
striatum (coordinates from bregma: +0.5 AP, -2.1 LM, -3.2 DV) of young adult male mice (~8 
wks; C57BL/6J) at the rate of 500 nL per minute. The animals were allowed to rest for 1 week 
after surgery before any further experiments. First, we evaluated the safety aspects of this virus 
and determined whether any leak, basal expression of the NS5A protein driven by 4xMRE would 
have any significant effects on the striatal motor functions of these animals. Throughout 43 days 
of behavioral testing, we did not detect any significant differences in the body weight of virus-
injected animals when compared with that of non-injected controls (Fig. 19A). In a simple 
accelerating rotorod performance experiment, both the AAV9-4xMRE-NS5A.eGFP and the 
control groups performed consistently, and no treatment effect was detected (Fig. 19B). In a 
sensorimotor adhesive removal test, the group injected with the NS5A virus performed comparably 
to the non-injected controls with the exception of one pre-surgery day and one experiment 35 days 
after surgery, which returned quickly to normal in the next evaluation (Fig. 19C). We concluded 
that striatal injection of AAV9-4xMRE-NS5A.eGFP did not cause any detectable sensory motor 
deficits. 
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AAV9 is a widespread viral vector that has been reported to have strong affinity to liver 
hepatocytes when injected systemically through the tail vein (Zincarelli et al., 2008). To assess the 
feasibility of leveraging a hepatitis virus protein as a transgene, we further performed H&E 
staining of the liver samples at the end of the above behavioral experiment and consulted an animal 
pathologist blinded to the experimental groups for evaluation of liver toxicity and for signs of 
chronic inflammation. No pathological signs of any kind normally associated with a viral infection 
were observed in the livers of either the virus-injected group or the non-injected control group 
(Fig. 20A). Mild acute extramedullary hematopoiesis (EMH) were observed in 1-2 animals in both 
groups of mice, of which, EMH presentation in one virus-injected animal was slightly more 
pronounced, but still was deemed within normal physiology. No animals exhibited any chronic or 
pathological symptoms that would indicate a liver-related disease. Further, the liver weight of 
animals injected with AAV9-4xMRE-NS5A.GFP did not significantly differ compared to non-
injected controls (Fig. 20B). In addition, separate groups of animals were injected with the virus 
as described above and were filmed while free-behaving in a test cage over a period of ~2 months 
after injection. We observed no abnormal behaviors from animals injected with AAV9-4xMRE-
NS5A.eGFP when compared to that of non-injected animals and also animals injected with 
AAV9.CMV-eGFP (Representative video links at final time point: GFP and NS5A). 
4.3.3  Focal ischemic stroke induces the expression of NS5A.eGFP in animals received 
striatal injection of AAV9-4xMRE-NS5A.eGFP 
Three hr prior to sacrifice, the animal group for the sensorimotor testing and the liver 
toxicity evaluation was treated with 50 min MCAO. Using anti-NS5A antibody (abcam ab13833; 
FitC secondary antibody Sigma F0257), we found that this ischemic stroke treatment was 
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sufficient to elicit the expression of NS5A.eGFP in regions surrounding the striatum (Fig. 21). We 
observed that NS5A was expressed in projection pyramidal neurons in the cortex (Fig. 21B) and 
other neuronal subtypes in the cortex (Fig. 21C) and in thalamic regions (Fig. 21D). Curiously, 
AAV9 is also known to transduce astrocytes and oligodendrocytes (Aschauer et al., 2013) but we 
did not observe any non-neuronal cells expressing detectable amounts of the NS5A protein. Within 
the striatal area, we have not detected the expression of any NS5A.eGFP. 
4.3.4  Preventative treatment of AAV9-4xMRE-NS5A.eGFP reduces striatal infarct                                                                                                                                                                                                                                                 
In a separate cohort of animals, mice were injected with either AAV9-4xMRE-NS5A.eGFP 
or AAV9-CMV-eGFP to the striatum identically as described above. After 3-4 weeks from 
injection, we subjected these animals to 50 min MCAO and evaluated the striatum 24 hr after 
ischemic reperfusion. We sectioned and stained the striatum with triphenyltetrazolium chloride 
(TTC) and evaluated the infarction ratio of only the ipsilateral striatum (StriatumInfarct/StriatumTotal) 
with an experimenter blinded to the treatment groups. The results show that the animals injected 
with AAV9-4xMRE-NS5A.eGFP exhibited significantly reduced striatum infarct ratio compared 




Figure 18. Construction and validation of the pAAV-4xMRE-NS5A.GFP plasmid. 
A. The pre-viral pAAV-4xMRE-NS5A.eGFP plasmid flanked by AAV2 ITRs is generated by 
traditional restriction enzyme cloning of the 4xMRE-NS5A.eGFP construct into the widely used 
pAAV-CMV-eGFP vector. B. Cortical culture neurons were transfected with luciferase and either 
pAAV-4xMRE-NS5A.GFP or a control plasmid. After 24 hr of 60 uM TBOA incubation, the 
experimental group transfected with pAAV-4xMRE-NS5A.GFP expressed significantly more 
luciferase, a signal of cellular viability. Mean of differences ± SEM: 16.132 ± 5.32669. n=5. * 






Figure 19. Striatum injection of AAV9-4xMRE-NS5A.eGFP does not cause behavioral deficits. 
A.  Body weight of animals injected with the experimental virus did not differ from that of the 
non-injected control group. B. Rotorod performance did not differ significantly in animals injected 
with the AAV9-4xMRE-NS5A.eGFP virus. C. Virus-injected animals performed significant 
worse in the adhesive removal test in two days of the experiments. However, one of the significant 
days was pre-surgery and the other quickly returned to baseline in the next session. Mean ± SEM 




Figure 20. Liver of animals treated with striatal injection of AAV9-4xMRE-NS5A.GFP is not affected. 
A. Mice (~4 months of age) received intracerebral injection of AAV9-4xMRE-NS5A.GFP do not 
show any abnormal liver pathology in H&E stained sections after 5 weeks when compared to non-
injected controls. Minor acute extramedullary hematopoiesis was observed in 1-2 animals of both 
groups. Scale bar = 100 uM. B. Wet liver weight of these animals taken immediately after 
perfusion were not significantly different. Mean ± SEM; Control: 1.55 ± 0.087, NS5A: 1.33 ± 




Figure 21. 4xMRE-driven expression of NS5A after focal ischemic stroke. 
MCAO (50 min) of mice 5-6 weeks after striatum injection of AAV9-4xMRE-NS5A.GFP 
induces the expression of NS5A.GFP within 3 hrs. We observed sparsely distributed expression 
of NS5A.GFP in neurons throughout the ipsilateral side. Expression was observed in cortex layer 
projection pyramidal neurons (A), and locally synapsing neurons in the cortex (B) and in the 
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thalamic regions (C). These areas are typically in the ischemic penumbra. Curiously, we did not 
detect any expression of NS5A.GFP in glia anywhere or in neurons within the ischemic core 




Figure 22. 4xMRE-driven expression of NS5A.eGFP reduces infarct area in focal ischemic stroke. 
Blinded evaluation of mice brain injected with the NS5A virus after 50 min MCAO found a 
significant reduction of infarct volume in the region compared with that of animals injected with 
AAV9-CMV-GFP. Infarct ratio: StriatumInfarct/StriatumTotal. Striatum infarct ratio mean ± SEM: 




The HCV genome is comprised of 9.6 kb of RNA containing a single open reading frame 
of ~3000 amino acids, flanked by un-translated regions highly conserved between virus genotypes 
(Tellinghuisen et al., 2007). The translated polyprotein is processed by both host and viral 
proteases, resulting in 10 individual virus proteins: the structural proteins core, E1, E2, the 
viroporin p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B 
(Tellinghuisen et al., 2007). The structure of NS5A is composed of three domains, with domain 1 
as the only domain with a defined tertiary structural. Domain 1 contains coordinated cysteine 
motifs at the n-terminus that binds 1 atom of zinc that is critical for HCV replication (Ross-
Thriepland & Harris, 2015), a disulfide bond towards the C-terminus, and a known 
phosphorylation site near a lipid droplet motif (Ross-Thriepland & Harris, 2015). In addition, there 
is evidence that NS5A domain 1 can form highly stable dimers, although the exact conformation 
has not been determined (Tellinghuisen et al., 2005; Love et al., 2009). 
While the precise mechanism of NS5A neuroprotection remains to be confirmed, there are 
a few proposed mechanisms targeting the Kv2.1-dependent cell death pathway. Initial 
characterization of NS5A’s effects on Kv2.1 in hepatocytes found that NS5A inhibits p38 
phosphorylation of Kv2.1 S800, which is a necessary step in the expression of the death-inducing 
currents (Mankouri et al., 2009). It was later determined that this effect may be the result of direct 
inhibition of mixed lineage kinase 3 (MLK3) by NS5A, which prevents the activation of p38 kinase 
(Amako et al., 2013). However, NS5A has also been shown to inhibit the phosphorylation of Kv2.1 
channels at the Y124 residue, which is the target of Src kinase (Norris et al., 2012). While NS5A 
can prevent phosphorylation by Src kinase in general, the non-phosphorylable mutant Kv2.1 
S800A does not abolish the inhibition of NS5A on channel current (Norris et al., 2012). The 
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importance for the Y124 site is further supported by a later study revealing that the Kv2.1 Y124 
phosphorylation precedes and facilitates the S800 phosphorylation (He et al., 2015). It is possible 
that NS5A’s inhibition of death-permitting phosphorylation on Kv2.1 is redundant, as it has been 
proposed that a highly conserved polyproline sequence between domains 2 and 3 of NS5A 
mediates these effects by binding to a Src homology 3 (SH3) sequence (Macdonald et al., 2004), 
which is present in both Src and MLK3.  
Following the zinc-induced phosphorylation events at Kv2.1, the channel interacts with 
syntaxin, resulting in enhanced channel insertion (McCord & Aizenman, 2013; McCord et al., 
2014). Unlike previous neuroprotective strategies that interfere with the interaction between Kv2.1 
and syntaxin directly (McCord et al., 2014; Yeh et al., 2017), NS5A, which acts upstream, also 
suppresses basal Kv2.1 current (Norris et al., 2012). This likely corresponds with nominal kinase 
phosphorylation of Y124 and S800 in uninjured neurons. However, with the addition the 
conditional promoter 4xMRE, this effect on the basal current is abolished (Justice et al., 2018), 
presumably due to the significant reduced expression of NS5A in healthy neurons where cytosolic 
zinc remains tightly regulated.  
Several research groups, most notably in the field of cardiac arrest, have explored the 
utilization of conditionally expressed promoters, such as MRE. AAV delivery of DNA constructs 
driven by hypoxic response element (HRE) was utilized in a mouse ischemic heart model to great 
success by conditionally expressing angiogenic factors (Su et al., 2002) or heme oxygenase 
(Pachori et al., 2004). Expression driven by hypoxic response element in myocardium remains 
elevated for at least 4 hr after ischemia and return to baseline after 8 hr (Prentice et al., 1997). 
Designer promoters that combined several regulatory elements, so-called chimeric promoters, 
have been created to achieve even better signal-to-noise ratio between dormant and active states. 
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An early example combined Egr-1 binding site (EBS), MRE, and 3x hypoxia regulatory element 
(HRE) to form a promoter composed of EBS-MRE-3xHRE, capable of generating very low basal 
activity and up to 69 times the expression when stimulated with either metal or hypoxia (Lee et 
al., 2006). Innovations in cancer studies combine HRE with tumor-specific promoters to achieve 
great tissue specificity, for instance, the combination of estrogen regulatory element (ERE) and 
HRE in breast cancers and the combination of nestin promoter and HRE for targeting glioblastoma 
(Javan & Shahbazi, 2017). While we are the first to employ MRE alone in similar strategies in 
vivo, these studies inspire considerations of leveraging and optimizing the use of MRE in 
combination with various other regulatory elements and in the context of specific 
neurodegenerative diseases. 
A major challenge in treating neurodegenerative conditions is the ability to provide 
interventions to patients prior to the significant loss of neurons. This is difficult as the detection of 
a neurodegenerative disease may only come as symptoms appear, which already signifies 
significant cell death. While the identification of prodromal disease biomarkers is becoming more 
sophisticated, effective treatments remain elusive. We believe that the strategy of using an injury-
dependent promoter to drive the expression of a neuroprotectant, exemplified by 4xMRE-NS5A, 
is a very rational approach to a treatment design that can overcome these challenges. Its 
components are ideal for their roles: MRE relies on zinc for expression, essentially mirroring the 
Kv2.1-dependent cell death pathway; the protective agent NS5A has evolved to inhibit Kv2.1-
dependent cell death; and the AAV vector itself is known to induce stable expression of gene 
constructs to last for >7 years in patients in the muscle and the liver (Nathwani et al., 2011), and 
for >10 years in the human brain (Leone et al., 2012). Because the release of intracellular zinc 
relies on oxidative stress, which is a major component of most neurodegenerative conditions (Liu 
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et al., 2017), our work here has broad implications and represents an essential step towards an 
effect gene therapy for neurodegenerative diseases. 
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5.0 General Discussion 
This dissertation focused on targeting the Kv2.1-syntaxin interaction for neuroprotection. 
This was achieved in several ways. In chapter 2, we followed the proven workflow of determining 
a minimal binding amino acid sequence in a protein-protein interaction and generating a TAT-
linked peptide, namely TAT-C1aB. Administration of TAT-C1aB provided the first evidence that 
the Kv2.1-syntaxin interaction contributes to neuronal cell death in vivo. In chapter 3, we 
characterized the molecular actors in the binding between C1aB and syntaxin, allowing us to 
screen for small molecules that recapitulates these actions. In chapter 4, we took a step back and 
evaluated the in vivo potential of the HCV virus protein NS5A, which is a known upstream 
inhibitor to the Kv2.1-syntaxin interaction. Importantly, this last project geared towards the field 
of gene therapy, which represents one of the most promising approaches to combat 
neurodegenerative diseases. In this final discussion, I describe several unresolved questions 
regarding these topics and suggest paths to clarity wherever possible. Lastly, I propose an addition 
to the workflow that we have so far leveraged in our studies. 
5.1 The Kv2.1-syntaxin interaction 
We have repeatedly demonstrated that disrupting the Kv2.1-syntaxin interaction is a viable 
neuroprotective strategy. Most notably, this is shown in vivo with the TAT-C1aB peptide in 
chapter 2 and with the AAV9-4xMRE-NS5A.eGFP virus in chapter 4. In addition, preliminary 
data from our collaborators strongly suggest a neuroprotective effect of the 4xMRE-NS5A.eGFP 
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construct in fly models of chronic/progressive neurogenerative diseases. While these results 
clearly established Kv2.1-dependent cell death as an important mechanism in neurodegeneration 
in animal models, whether this mode of cell death exist in human patients is still a lingering 
question. To support the data presented here that demonstrated treatment efficacy in animal 
models, an in vivo detection method for a biomarker of Kv2.1-dependent cell death should be 
developed and confirmed with human patient tissues. This final step is necessary to make the 
connection from the decades of research in underlying mechanisms to clinical relevancy. 
A phospho-specific antibody was developed previously (Redman et al., 2007) to detect the 
phosphorylation of Kv2.1 S800 by p38 (pS800). An increase in phosphorylation of Kv2.1 S800 
after an injury in vivo would imply an enhanced Kv2.1-syntaxin interaction and provide evidence 
for our cell death model. Using the Kv2.1 pS800 antibody, I have attempted immunofluorescence 
staining of the mouse brain as well as western blot of the brain lysate 24 hr after MCAO. In both 
cases, I was unable to detect a significant difference between the ipsi- and the contra-lateral brain 
sample. In the immunofluorescence staining experiment, I was unable to produce Kv2.1-specific 
staining of the brain sections using the Kv2.1 pS800 antibody. Because this antibody is polyclonal, 
I expect further optimization of the staining protocol may be able to achieve at least weak staining 
of Kv2.1. Although any immunofluorescence staining with this particular antibody has not been 
demonstrated either in vitro or in vivo. In the western blot, the Kv2.1 pS800 band was very light, 
which is typical, and may have contributed to the inability to detect a difference in band intensity. 
To increase the concentration of phosphorylated Kv2.1 protein, the ischemic brain samples may 
be enriched by isolating regions most affected by the MCAO procedure. While these biochemical 
experiments are so far inconclusive due to technical challenges, overcoming these issues or 
developing an entirely different biomarker detection technique will allow the direct application of 
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these procedures to brain samples from human patients of ischemic stroke and of other 
neurodegenerative diseases. This is an important step in solidifying Kv2.1-dependent cell death as 
an important mechanism in humans prior to future efficacy studies. 
It is possible that TAT-C1aB and cpd5 merely induce localized disruption of the Kv2.1-
syntaxin binding to block the enhanced interaction and does not totally displace Kv2.1 from 
syntaxin. I acknowledge this possibility because the co-immunoprecipitation of Kv2.1 and 
syntaxin in CHO cells treated with 10 μM TAT-C1aB overnight did not immediately detect an 
effective decrease in proteins pulldown from either direction. My initial interpretation for this 
phenomenon is that other members of the SNARE complex, which are known to bind both Kv2.1 
and syntaxin, may act as scaffolding intermediates and retain both proteins in contact. Further, the 
docking model (chapter 3) shows that the C1aB peptide binds to a pocket surrounded by several 
syntaxin domains, making it likely that Kv2.1 interacts with syntaxin elsewhere. Note that I have 
only demonstrated the displacement of syntaxin from 15mer, not full-length, Kv2.1 peptides with 
TAT-C1aB and cpd5 in the cell-free peptide array (chapter 2, 3) (Yeh et al., 2017), which sidesteps 
the above two suggested scenarios. This is in contrast with previous results of McCord et al., 
where, in an overexpression system, full length C1a or C1a441-522 successfully displaced full-length 
Kv2.1 from syntaxin in a co-immunoprecipitation experiment (McCord et al., 2014). It is possible 
that the additional amino acids in the full-length C1a and C1a441-522 provide the steric volume 
necessary to fully unbind Kv2.1 from syntaxin and also disrupt any interactions provided by the 
other SNARE proteins. It is also likely that higher concentrations of TAT-C1aB is necessary to 
displace Kv2.1 and syntaxin in the overexpression systems, although 10 μM was the effective 
concentration to suppress the enhanced current of the pseudo-phosphorylated Kv2.1 S800E in the 
same overexpression CHO cell system (chapter 2) (Yeh et al., 2017). Nevertheless, full 
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displacement of Kv2.1 from syntaxin may not be necessary and small molecule-mediated 
destabilization of the interaction is clearly sufficient to inhibit the expression of the enhanced 
currents for neuroprotection. 
5.2 The role of Kv2.1 somatodendritic clusters 
A critical aspect of Kv2.1 not explored in this dissertation is the role of Kv2.1 
somatodendritic clusters in cell death. In neurons, Kv2.1 exists in micron-sized cluster that 
depends on a proximal restriction clustering (PRC) motif (Lim et al., 2000) and acts as protein 
trafficking hubs through its interactions with the endoplasmic reticulum anchoring proteins VAPA 
and VAPB (Johnson et al., 2018; Kirmiz et al., 2018). Although, not all Kv2.1 cluster appears to 
serve the same functions, or at least regulated in the same manner. Phosphoregulation of a Kv2.1 
target sequence motif (a. a. 720-745) can lead to Golgi-independent trafficking of the channel to 
the axon initial segment, which also form clusters that are not dependent on the PRC motif (Jensen 
et al., 2017). This subcellular localization draws similarities with the microtubule protein tau, 
which forms aggregates through liquid-liquid phase separation and is highly clustered also at the 
axon hillock (Wegmann et al., 2018). The connection between Kv2.1 and tau is not yet discovered.   
Kv2.1 clusters form in neurons in vivo, in primary cultured neurons, as well as in Kv2.1-
transfected HEK cells (O'Connell et al., 2006). Despite being the most prominent structural feature 
of Kv2.1, channels within the clusters have been shown to be a non-conducting population 
(O'Connell et al., 2010). Interestingly, these clusters are very dynamic structures and can be 
dispersed quickly when treated with some types of cell death stimulus. Merely 2 min of CO2 
treatment in rats will decluster Kv2.1 channel in hippocampus neurons (Misonou et al., 2005). 
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Brief excitatory treatment with 10 µM glutamate for 15 min is sufficient to decluster Kv2.1, 
recovering within 2 hr after the washout of glutamate (Cerda & Trimmer, 2011). The clustering of 
Kv2.1 was found to be dependent on the phosphorylation of Kv2.1 S603 by cyclin-dependent 
kinase 5 (Cerda & Trimmer, 2011), which is regulated by cyclin E1 (Shah et al., 2014). Zinc 
chelation also blocks declustering after ischemia (Aras et al., 2009b). Intriguingly, repeated 
electrical stimulation causes an increase in the number of Kv2.1 clusters in Aplysia bag cell 
neurons (Zhang et al., 2008). This is difficult to reconcile, as excitatory glutamate treatment readily 
declusters Kv2.1 in cultured rat hippocampal neurons (Misonou et al., 2004), and direct sciatic 
nerve stimulation also reduces Kv2.1 clusters in an intact rat motor neuron preparation (Romer et 
al., 2016). The observations in Aplysia bag cell neurons is likely specific to the animal model and 
I will avoid excessive conjectures. 
Kv2.1 clusters appear to play an integral part in the Kv2.1 cell death pathway, but their 
exact roles are just beginning to be explored. As mentioned, after treatment with several types of 
insults, Kv2.1 channels quickly decluster. However, a sublethal injury that does not kill the 
neurons can also decluster the channel. This treatment, commonly referred to as preconditioning, 
provides increased resistance and viability against later injuries that are typically deadly. This 
neuroprotection can be achieved by directly declustering Kv2.1 alone, without inducing injury or 
altering Kv2.1 channel kinetics (Justice et al., 2017). Because Kv2.1 itself has been observed to 
traffic to these clusters (Fox et al., 2015), and that declustering of Kv2.1 in neurons prevents the 
subsequent increase in channel current (Shah & Aizenman, 2014; Justice et al., 2017), it can be 
inferred that these clusters are required for the cell death-permitting de novo trafficking of Kv2.1. 
Although declustered Kv2.1 may become conducting over time (Zhang et al., 2008), it is unknown 
whether they contribute significantly in the context of enhanced death-permitting Kv2.1 current. 
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Interestingly, while it is unknown how the Kv2.1-syntaxin interaction fit into the clustering 
pathways, VAPA has been previously shown to bind effectively to both v-SNAREs and t-
SNAREs, including syntaxin 1A (Weir et al., 2001). All these evidences point towards significant 
crosstalk between Kv2.1’s cell death and clustering pathways. Further investigations are necessary 
to unravel these two interconnected phenomena.  
5.3 Further AAV9-4xMRE-NS5A.eGFP characterization 
Several important lingering questions regarding AAV9-4xMRE-NS5A.eGFP remain and 
may require different approaches to confirm the findings. First, I was surprised with the expression 
pattern of the virus, which was very widespread but also highly selective. Typically, gene 
expression with any viral vector in intracerebral injections is very localized and will infect most 
cell types near the injection site to some degree (Aschauer et al., 2013). Infection of neurons 
outside of the striatum may be the result of virus diffusion and the relatively large volume (5 uL) 
of our injection. However, it is strange that we did not observe any expression in the striatum, 
which may be indicative that the stroke treatment is too severe in the ischemic core, but protease 
activity is not expected to be this thorough in 3 hr. It is not known if there are any differences in 
the expression activity of MRE in the striatum vs the cortex caused by zinc buffering activities or 
other factors. While AAV9 is known to transduce cortical neurons with high efficiency, which we 
observed, we expected to observe some degrees of NS5A expression in astrocytes or other glia, 
which was completely absent. In fact, the pathway of oxidative damage-induced release of 
cytosolic zinc, activating MTF-1, is known to exist in astrocytes as well (Kruczek et al., 2009). 
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Though the lack of expression in astrocytes may be due to fact that they are more resistance to 
intracellular zinc liberation (Aizenman et al., 2000).  
The combination of virus injection, focal ischemic stroke, and inducible promoter may 
have caused the expression pattern of the NS5A protein to be too difficult to characterize. 
Essentially, all three factors must be in effect for the observation of the protein expression. To 
remedy this, in situ hybridization of the 4xMRE-NS5A.eGFP DNA construct may be used to 
observe the true infection efficiency of the virus. For the purpose of characterizing the expression 
pattern only, global ischemia through bilateral carotid artery occlusion may be useful to induce a 
more consistent ischemic insult throughout the brain parenchyma. In addition, because we have 
observed infection of large pyramidal neurons in the cortex layers, it may be possible to observe 
real time expression of the protein during ischemia with a cranial window and a powerful multi-
photon microscope. Lastly, because NS5A is known to suppress basal Kv2.1 current (Norris et al., 
2012), transient expression of NS5A driven by 4xMRE must be quantified to provide a precise 
active vs dormant ratio, which then allows for future improvements and comparisons with other 
inducible promoters. These works will contribute to fully characterize the in vivo action of the 
4xMRE-NS5A.eGFP construct and provide the basis for future studies. 
AAV9 has been reported to be an effective viral vector in the brain and we sought to see if 
a more widespread treatments in the CNS is sufficient to provide neuroprotection to a larger brain 
region. In a separate cohort of animals from the data presented in chapter 4, we injected the same 
titer of AAV9-4xMRE-NS5A.eGFP virus into the lateral ventricle, induced 50 min MCAO after 
3-4 weeks, and quantified the infarct ratio of the total brain as opposed to only the striatum region. 
Blinded evaluation of the brain sections stained with triphenyltetrazolium chloride found a 
trending, but not yet significant, effect of the AAV9-4xMRE-NS5A.eGFP virus injection 
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compared to that of AAV9.CMV.eGFP (Fig. 23). We believe that this finding is promising and 
warrants further investigation for ways to enhance systemic viral transduction, or even by the 
conjugation of NS5A with the TAT domain, which is an idea explored by Ma et al. in the nasal 
delivery of AAV2-TAT-BDNF (Ma et al., 2016). 
 
Figure 23. Infusion of AAV9-4xMRE-NS5A.eGFP virus (~5.30x108 GC) into the lateral ventricle did not 
provide significant neuroprotection against MCAO. 
After 3-4 weeks from the virus infusion, mice were treated with 50 min MCAO. Mice brains were 
stained with TTC 24 hr after stroke and evaluated by a blinded investigator. Infarct ratio mean ± 
SEM: NS5A 0.036 ± 0.01, GFP 0.071 ± 0.01. N = 6 for NS5A, n = 4 for GFP. Unpaired t-test.  
5.4 Gene therapy in clinical trials and AAVs 
Since the authorization of the first gene transfer study that took place at the National 
Institutes of Health in 1989, the number of completed clinical trials on this topic is nearing 3000, 
with participations in nearly 40 countries (Ginn et al., 2018). Overwhelmingly, cancer and 
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inherited monogenic diseases are the target of most of these studies, accounting for ~75% of all 
completed gene therapy clinical trials. Those that targets neurological diseases account for only 
1.8% (n = 47) of all completed trials by 2017 (Ginn et al., 2018). While the use of AAV as the 
viral vector is in only 7.6% of all gene therapy clinical trials (Ginn et al., 2018), it is the most 
widespread vector for use in neurological diseases today (Choudhury et al., 2017).  
Despite the amassing clinical data, only a handful of gene therapies so far have been 
approved for use in humans. This is a rapidly improving situation. In a statement released by the 
FDA commissioner Scott Gottlieb on January 15, 2019, the FDA expects to approve 10 to 20 cell 
and gene therapy products per year by 2025. The first approved gene therapy product, Gendicine 
(Sibiono), passed its review by the Chinese state FDA in 2003. Gendicine is an adenovirus, a much 
larger viral vector than AAV, with designations for squamous cell carcinoma and overexpresses 
p53 to induce cancer cell death with a great safety profile (Zhang et al., 2018). Since then, 6 more 
gene therapy products have been approved for clinical use, including, with approval by the United 
States FDA in 2017, Yescarta (an ex vivo chimeric antigen receptor T-cell (CAR-T) therapy for 
large B-cell lymphoma; Gilead) and Kymriah (a CAR-T therapy for B-cell acute lymphoblastic 
leukemia; Novartis). Just this year, Zolgensma (AVXS-101; Novartis, formerly AveXis) was just 
approved in May 2019, albeit with the steep price tag of over $2 million dollars.  
AVXS-101 is a gene replacement therapy for type 1 spinal muscular atrophy (SMA1), 
which is the second most common fatal autosomal recessive disorder after cystic fibrosis. Infants 
afflicted with the SMA1 mutation have homozygous deletion of the survival motor neuron 1 
(SMN1) gene in motor neurons and experience rapid muscle atrophy often leading to respiratory 
failure within two years of age (D'Amico et al., 2011). One-time intravenous infusion of AVXS-
101 in patients significantly improved respiratory and motor functions and, at 20 months of age, 
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all 15 patients in the first clinical trial survived, compared to the 8% historical rate at the same age 
(NCT02122952) (Mendell et al., 2017). In a later study, the group found treated patients to have 
reduced hospitalization and improved behavioral outcomes, allowing the infants to preserve 
respiratory functions, the ability to swallow, and to develop speech (Al-Zaidy et al., 2019). AVXS-
101 is a self-complementary AAV9 which expresses the SMN1 gene under the control of the 
chicken β-actin promoter and has been shown to be able to transduce 60% of motor neurons when 
injected IV (5 x 1011 GCs) into neonatal mice (Foust et al., 2010). Self-complementary AAV 
genomes have been shown to have significantly increased transduction efficiency by bypassing 
the bottleneck of needing the host cell DNA polymerase to generate a double-stranded genome 
(McCarty et al., 2003). The clinical trial also reported a brief asymptomatic elevation of liver 
enzymes, which was assumed to be related to the viral vector and was easily overcome with “a 
brief course of steroids” (Al-Zaidy et al., 2019). 
AVXS-101 represents an important success story of utilizing AAV vectors safely and to 
great effect in the clinical settings. AAV has become a preferred vector for gene therapy for several 
distinct advantages. AAV-delivered genes can exist in an episomal state with a low rate of genomic 
integration into the host genome (McCarty et al., 2004). The immunogenicity is very mild due to 
its small size (Bessis et al., 2004). AAVs in general are also relatively safe to handle, and it is 
relatively easy to produce titers at high purity. AAV9 have also been found to be able to penetrate 
the blood brain barrier (Manfredsson et al., 2009), which avoids the highly invasive intracerebral 
and intrathecal injections. In addition, AAV2 nasal delivery of large TAT-linked proteins can 
achieve widespread distribution of the cargo (Ma et al., 2016). However, there exist one key 
shortcoming of the AAV vector and that is its relatively small genomic capacity (4.8 kb) compared 
to the other popular options in retrovirus (gammaretrovirus and lentivirus; ~8.5 kb), and 
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adenovirus (10 kb) (Choudhury et al., 2017). Experiments with larger virus particles, such as 
amplicons based on recombinant herpes simplex virus can carry cargo up to 150 kb but is difficult 
to purify  (Choudhury et al., 2017). This limits the size of cargos for AAV vectors, which 
practically eliminates its consideration for gene-replacement therapies in some monogenetic 
diseases. 
Recombinant AAVs with different serotypes allow for infectious affinity for specific cell 
types. Directed evolution forces the brute force generation of AAV capsids with display peptides 
that has incredible selectivity for almost any cell type desired (Grimm & Zolotukhin, 2015; 
Deverman et al., 2016). In 2016, Korbelin et al. disclosed a custom AAV capsid (AAV-BR1) 
generated through directed evolution to specifically target brain endothelial cells. Infected cells by 
this vector have been shown to express genomic constructs for at least two years. I became 
interested in this capsid as I was studying the effects of the neuroprotective TAT-linked peptide 
(TAT-C1aB) in ischemic stroke. I rationalized that the source of brain ischemia begins at the brain 
vasculature, and brain endothelial cells can be manipulated to induce the expression of TAT-C1aB 
during ischemic conditions. Dr. Korbelin generously provided me with the plasmid for his capsid. 
However, I was unable to replicate their results using a simple GFP cargo. Continuing this path 
has been difficult due to the lack of an in vitro system for verifying the virus stock that I have 
grown, despite PCR confirmation of the genomic load. Nevertheless, I remain optimistic that 
similar developments in the pool of available AAV capsids will make significant clinical impacts 
in the near future. 
 119 
5.5 TAT-linked peptides as AAV cargo 
Limitations in cargo size is the predominant shortcoming of AAV vectors. TAT-linked 
peptides that contain optimized sequences, such as TAT-C1aB (chapter 2) (Yeh et al., 2017), TAT-
CDB3 (Brittain et al., 2011b), or TAT-NR2B9c (Ballarin & Tymianski, 2018) may be the ideal 
cargoes for their significantly reduced length compared to their parent proteins. In the introduction 
(section 1.8), I presented the workflow of protein binding sequence optimization through 
techniques such as the SPOT peptide array, followed by the construction of the TAT-linked 
peptide. Here, I propose the novel transition of encoding the TAT-linked peptides developed in 
this manner as the genetic cargo for AAV vectors. This strategy has several distinct advantages 
that makes it the rational continuation. Unlike synthetic molecules commonly used in typical 
pharmacology, peptide-based treatments can be produced by the patients’ own cells. In this setting, 
treatment expressed from within the cells via an inducible promoter based on cytosolic conditions 
is, by definition, the fastest treatment possible for a non-preemptive response. Further, AAV 
treatment represents a nearly permanent solution for the treatment of chronic or subchronic 
conditions, such is the case with most neurodegenerative diseases. For example, patients with 
Canavan disease have a mutation of the aspartoacylase gene (ASPA) and accumulates a damaging 
level of N-acetylaspartate (NAA). With AAV2-mediated gene replacement therapy via direct 
intraparenchymal infusions, NAA levels were significantly decreased in Canavan disease patients 
compared to non-treated controls and significantly improved motor functions for 10 years in some 
(Leone et al., 2012). Lastly, and importantly, this strategy allows for massive optimization of the 
genetic cargo space, which is an immense opportunity to finetune and extend control over the 
expression of the TAT-linked molecule through cis-regulatory elements and to have the ability to 
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express multiple proteins in tandem. An interesting concept is to include means of removing the 
gene construct as part of the gene itself as a form of reversible gene therapy. 
All gene therapies in the clinic today are remarkably simple overexpression constructions 
with little means of control compared to the various promoters and regulatory elements available 
in research studies. I would like to highlight an experiment presented by Siprashvili & Khavari in 
2004 using a lentiviral vector that contains the erythropoietin (EPO) gene driven by the 
glucocorticoid regulatory element (GRE) (Siprashvili & Khavari, 2004). Importantly, this GRE-
EPO gene construct is placed in tandem with Cre-fused estrogen receptor (Cre-ER) using an 
internal ribosomal entry sequence (IRES) and flanked by loxP sites. This meant that tamoxifen 
injection will induce cre-mediated removal of this exact foreign DNA. This viral treatment is 
injected intradermally into the skin, where topical applications of a glucocorticoid (Clobetasol) 
can induce expression of EPO for ~1 month. Because the skin has an extensive ability to regenerate 
itself, it is conceivable that any gene therapy can be totally reversed with the inclusion of an 
artificial death switch, such as one that have auto-proteolytic activity to release activated caspases 
after chemical-induced dimerization (CID) of designer molecules that is otherwise biologically 
inert (Steller, 1998). The GRE-EPO study also highlighted the idea of transducing skin for 
affecting a distant target (EPO must reach the bone marrow to stimulate red blood cell production). 
Undoubtedly, TAT-linked peptides can reach the CNS rapidly if expressed by the skin, as 
intraperineal injections of TAT-C1aB-FitC reach the brain vasculature within 5 minutes (chapter 
2) (Yeh et al., 2017). In fact, AAV1 and AAV6 are both effective in transducing skin keratinocytes 
(Ellis et al., 2013) and can act as the ideal viral vector for this skin-to-CNS treatment concept. 
With the advent of these novel approaches, future gene therapy may not have to be permanent or 
even invasive. 
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Towards the goal of a gene therapy mediated via a TAT-linked peptide, I have attempted 
to use the chimeric promoter EBS-MRE-2xHRE, which is similar to the EBS-MRE-3xHRE 
characterized by Lee et al. (Lee et al., 2006), to drive the expression of TAT-C1aB. This plasmid 
(pAAV-EBS-MRE-2xHRE-TAT.C1aB) was found to be neuroprotective in our in vitro neuronal 
culture model (Fig. 24A). However, after injection of the virus (AAV9-EBS-MRE-2xHRE-
TAT.C1aB) into the mouse lateral ventricle, the animals inexplicably gained significantly more 
body weight (Fig. 24B) and exhibited exacerbated infarct size after 50 min MCAO compared to 
that of the AAV9-CMV-eGFP controls (Fig. 24C). We speculate that the high sensitivity of the 
chimeric promoter may have led to leak expression and caused long-term systemic effects, such 
as disrupting the Kv2.1-syntaxin binding in the pancreas, which is known to be important for 
proper insulin secretion (Greitzer-Antes et al., 2018). Re-construction of this plasmid using the 
MRE promoter (4xMRE-TAT.C1aB) found intrinsic neurotoxicity in vitro and was not further 
pursued in vivo. These results are important lessons that while in vitro systems can act as surrogates 
for evaluating cell death mechanisms, it does little to recapitulate the entire animal or reflect the 
systemic effects of the treatments, which can override any beneficial actions. Nevertheless, 
because the plasmid cargo itself has been shown to be effective in the many other contexts 
presented here, I remain optimistic in this approach in future studies.
 
Figure 24. Preliminary evaluation of the gene construct EBS-MRE-2xHRE-TAT.C1aB. 
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A. In vitro evaluation of pAAV-EBS-MRE-2xHRE-TAT.C1aB found significant neuroprotective 
actions against overnight applications of 60 uM TBOA. Mean difference in relative luciferase 
expression ± SEM: 32.14 ± 7.88. *p = 0.0065; paired t-test. N = 7. B. In vivo infusion of AAV9-
EBS-MRE-2xHRE-TAT.C1aB in the mouse brain caused significant weight gain after 3-4 weeks. 
Mean weight (g) ± SEM: C1aB 28.98 ± 1.0, GFP 25.33 ± 0.33. n = 4 for both groups. Unpaired t-
test; *p = 0.0137. C. Mice treated with the experimental virus did not exhibit reduce infarct volume 
compared with those treated with the control virus. Infarct ratio ± SEM: C1aB 0.098 ± 0.22, GFP 
0.069 ± 0.013. n = 6 for C1aB, n = 5 for GFP. Unpaired t-test. 
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5.6 Closing Remarks 
There is an increasing indication of Kv2.1 involvement in several neurodegenerative 
diseases (McCord & Aizenman, 2014; Shah & Aizenman, 2014; Chao et al., 2018; Yu et al., 2018). 
As we further understand the role of Kv2.1 in these diseased conditions, it becomes increasingly 
more important to design and evaluate potential protective agents to target this pathway, such as 
the three presented here: TAT-C1aB, cpd5, and AAV9-4xMRE-NS5A.eGFP. As these 
experiments moved forward, we recruited more collaborators and incorporated highly 
interdisciplinary approaches to reach our goals. I believe this is the case for all translational 
research today and will be reflected in an increase in the sophistication and the effectiveness of 
future clinical treatments. I would like to lastly remark that the availability of genomic tools and 
viral vectors are increasing in a spectacular rate. Together with the increasing understanding of 
constructing properly regulated gene elements, this technology may one day become a 
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